Ether lipid biosynthesis promotes lifespan extension and enables diverse pro-longevity paradigms in Caenorhabditis elegans
Abstract
Biguanides, including the world’s most prescribed drug for type 2 diabetes, metformin, not only lower blood sugar, but also promote longevity in preclinical models. Epidemiologic studies in humans parallel these findings, indicating favorable effects of metformin on longevity and on reducing the incidence and morbidity associated with aging-related diseases. Despite this promise, the full spectrum of molecular effectors responsible for these health benefits remains elusive. Through unbiased screening in Caenorhabditis elegans, we uncovered a role for genes necessary for ether lipid biosynthesis in the favorable effects of biguanides. We demonstrate that biguanides prompt lifespan extension by stimulating ether lipid biogenesis. Loss of the ether lipid biosynthetic machinery also mitigates lifespan extension attributable to dietary restriction, target of rapamycin (TOR) inhibition, and mitochondrial electron transport chain inhibition. A possible mechanistic explanation for this finding is that ether lipids are required for activation of longevity-promoting, metabolic stress defenses downstream of the conserved transcription factor skn-1/Nrf. In alignment with these findings, overexpression of a single, key, ether lipid biosynthetic enzyme, fard-1/FAR1, is sufficient to promote lifespan extension. These findings illuminate the ether lipid biosynthetic machinery as a novel therapeutic target to promote healthy aging.
Editor's evaluation
This paper explores the molecular basis underlying metformin treatment to understand why it is such an effective drug for improving age-related health and lifespan. Using C. elegans as a model organism in which to do this, the paper hones in on the role of ether lipid biosynthesis as an effector of metformin, and more broadly as a process implicated in extending lifespan in response to diet, TOR signalling and mitochondrial based interventions. The compelling data substantially support the conclusions and the better understanding of biguanide impact on metabolism is highly important in the field.
https://doi.org/10.7554/eLife.82210.sa0eLife digest
Metformin is the drug most prescribed to treat type 2 diabetes around the world and has been in clinical use since 1950. The drug belongs to a family of compounds known as biguanides which reduce blood sugar, making them an effective treatment against type 2 diabetes.
More recently, biguanides have been found to have other health benefits, including limiting the growth of various cancer cells and improving the lifespan and long-term health of several model organisms. Epidemiologic studies also suggest that metformin may increase the lifespan of humans and reduce the incidence of age-related illnesses such as cardiovascular disease, cancer and dementia. Given the safety and effectiveness of metformin, understanding how it exerts these desirable effects may allow scientists to discover new mechanisms to promote healthy aging.
The roundworm Caenorhabditis elegans is an ideal organism for studying the lifespan-extending effects of metformin. It has an average lifespan of two weeks, a genome that is relatively easy to manipulate, and a transparent body that enables scientists to observe cellular and molecular events in living worms.
To discover the genes that enable metformin’s lifespan-extending properties, Cedillo, Ahsan et al. systematically switched off the expression of about 1,000 genes involved in C. elegans metabolism. They then screened for genes which impaired the action of biguanides when inactivated. This ultimately led to the identification of a set of genes involved in promoting a longer lifespan. Cedillo, Ahsan et al. then evaluated how these genes impacted other well-described pathways involved in longevity and stress responses.
The analysis indicated that a biguanide drug called phenformin (which is similar to metformin) increases the synthesis of ether lipids, a class of fats that are critical components of cellular membranes. Indeed, genetically mutating the three major enzymes required for ether lipid production stopped the biguanide from extending the worms’ lifespans. Critically, inactivating these genes also prevented lifespan extension through other known strategies, such as dietary restriction and inhibiting the cellular organelle responsible for producing energy. Cedillo, Ahsan et al. also showed that increasing ether lipid production alters the activity of a well-known longevity and stress response factor called SKN-1, and this change alone is enough to extend the lifespan of worms.
These findings suggest that promoting the production of ether lipids could lead to healthier aging. However, further studies, including clinical trials, will be required to determine whether this is a viable approach to promote longevity and health in humans.
Introduction
Metformin is the first line therapy for type 2 diabetes and the most frequently prescribed oral hypoglycemic medication worldwide (Inzucchi et al., 2012). Human epidemiologic studies note an association between metformin use and decreased incidence of cancer (Evans et al., 2005; Yuan et al., 2013). In addition, metformin extends lifespan in invertebrate and vertebrate models (Cabreiro et al., 2013; Martin-Montalvo et al., 2013; Onken and Driscoll, 2010), and therefore may reduce aging-related diseases in humans (Barzilai et al., 2016). Nonetheless, our understanding of the molecular pathways governing the health-promoting effects of metformin is only just beginning to emerge. Our previous work identified a conserved signaling axis connecting mitochondria, the nuclear pore complex, and mTORC1 inhibition that is required for metformin-mediated extension of lifespan in Caenorhabditis elegans and inhibition of growth in worms and human cancer cells (Wu et al., 2016). The energy sensor AMP-activated protein kinase (AMPK) is not necessary for metformin-induced growth inhibition in C. elegans but is required for the drug’s pro-longevity effects (Cabreiro et al., 2013; Onken and Driscoll, 2010; Chen et al., 2017). Consistently, mechanistic studies indicate that the longevity-promoting transcription factor SKN-1/nuclear factor erythroid 2-related factor (Nrf) is required for biguanide-mediated lifespan extension (Cabreiro et al., 2013; Onken and Driscoll, 2010). The relationship of these metformin longevity response elements to each other and their hierarchy in the biological response to biguanides remains unknown. Thus, the mechanisms by which metformin exacts its beneficial effects on health are likely to be branching and complex.
The importance of ether lipids, a major structural component of cell membranes, to aging and longevity is not fully established. Ether lipids are involved in the maintenance of general membrane fluidity and in the formation of lipid rafts within microdomains, which are important for promotion of membrane fusion and cellular signaling (Glaser and Gross, 1994; Komljenovic et al., 2009; Marrink and Mark, 2004). Ether lipids have broad roles in the regulation of cell differentiation (Davies et al., 2001; Facciotti et al., 2012; Rodemer et al., 2003; Teigler et al., 2009), cellular signaling (Thukkani et al., 2002; Albert et al., 2003), and reduction of oxidative stress through their action as antioxidants (Morand et al., 1988; Zoeller et al., 1988; Reiss et al., 1997; Maeba et al., 2002). Humans deficient in ether lipid biogenesis suffer from rhizomelic chondrodysplasia punctata (RCDP), a rare genetic disorder, which results in skeletal and facial abnormalities, psychomotor retardation, and is uniformly fatal typically before patients reach their teenage years (White et al., 2003). Thus, current evidence linking alterations in ether lipid levels to aging and longevity in humans is strictly correlative (Gonzalez-Covarrubias et al., 2013; Pradas et al., 2019).
Ether lipids, which are structurally distinct from canonical phospholipids, have a unique biosynthetic pathway through which a fatty alcohol is conjugated to the glycerol backbone at the sn-1 position via an ether linkage. Ether lipid precursors are first synthesized by enzymes associated with the membranes of peroxisomes (Ghosh and Hajra, 1986; Hardeman and van den Bosch, 1989; Singh et al., 1993.) The main enzymes involved in ether lipid biosynthesis within the peroxisomal matrix are glyceronephosphate O-acyltransferase (GNPAT) and alkylglycerone phosphate synthase (AGPS). Fatty acyl-CoA reductase 1 (FAR1) supplies most of the fatty alcohols used to generate the ether linkage in the precursor, 1-O-alkyl-glycerol-3-phosphate. This precursor is then trafficked to the endoplasmic reticulum (ER) for acyl chain remodeling to produce various ether lipid products (Hua et al., 2017). In C. elegans, loss-of-function mutations of any of the three main enzymes involved in human ether lipid biosynthesis, acl-7/GNPAT, ads-1/AGPS, and fard-1/FAR1, result in an inability to produce ether-linked lipids, as in humans, and has been reported to shorten worm lifespan (Drechsler et al., 2016; Shi et al., 2016). Worms and human cells deficient in ether lipids exhibit compensatory changes in phospholipid species, including increases in phosphatidylethanolamines and phosphatidylcholines containing saturated fatty acids (Rodemer et al., 2003; Benjamin et al., 2013). However, in contrast to humans, ether lipid deficient nematodes develop to adulthood at a normal rate, providing an opportunity to determine the biological roles of ether lipids in aging and longevity without pleiotropies associated with developmental rate.
Here, we show that the ether lipid biosynthetic machinery is necessary for lifespan extension stimulated by metformin or the related biguanide phenformin in C. elegans. Metabolomic analysis indicates that phenformin treatment drives increases in multiple phosphatidylethanolamine-containing ether lipids through direct biguanide action on C. elegans rather than on the bacterial food source. Interestingly, requirement for the ether lipid biosynthetic genes extends to multiple genetic longevity paradigms, including defective mitochondrial electron transport function (isp-1), defective pharyngeal pumping/caloric restriction (eat-2), and compromises in mTOR complex 1 activation (raga-1). We show that overexpressing fard-1, the enzyme that produces fatty alcohols for ether lipid biogenesis in C. elegans, extends lifespan, supportive of the idea that alterations in the ether lipid landscape alone is sufficient to promote healthy aging. Mechanistically, ether lipids promote longevity downstream of biguanide action through activation of metabolic stress defenses and somatic lipid redistribution driven by the transcription factor SKN-1/Nrf. These data suggest that a heretofore unappreciated role for ether lipids is to enable organismal-level, longevity-promoting stress defenses.
Results
Genes responsible for ether lipid biosynthesis are necessary for biguanide-induced lifespan extension
A prior screen of ~1000 metabolic genes for RNA interference (RNAi) knockdowns that interfere with the growth-inhibitory properties of a high, 160 mM dose of metformin in C. elegans (utilized to maximize the sensitivity and specificity of our assay to identify true epistatic candidates) (Wu et al., 2016), yielded fard-1 and acl-7, which are required for ether lipid biosynthesis. Ether lipids are distinguished from canonical phospholipids as the latter contain exclusively fatty acids conjugated to glycerol, whereas ether lipids contain a fatty alcohol conjugated to the glycerol backbone at the sn-1 position via an ether linkage (Figure 1A). Confirming our screen results, granular, quantitative analysis following RNAi knockdown of fard-1 and acl-7 reveals significant resistance to biguanide-induced growth inhibition (Figure 1—figure supplement 1A). Our lab has previously demonstrated that biguanide effects on growth in C. elegans share significant overlap mechanistically with the machinery by which metformin extends lifespan in the worm, thus suggesting that modulation of ether lipid biosynthesis may also be responsible for the lifespan-extending properties of the drug (Wu et al., 2016). Indeed, loss-of-function mutations in any of three genes encoding enzymes required for ether lipid biosynthesis, fard-1, acl-7, or ads-1, significantly abrogate lifespan extension induced by lifespan-extending doses of metformin (50 mM) and the related biguanide phenformin (4.5 mM) (Figure 1B–G). Loss-of-function of ads-1 and acl-7 may display a modest increase in lifespan with metformin administration but display a percentage median lifespan increase significantly reduced in comparison to wild-type controls (Figure 1B–G, and throughout manuscript see Supplementary file 1 for all tabular survival statistics and biological replicates). Confirming that these mutations confer resistance to metformin by compromising ether lipid synthetic capacity, RNAi knockdowns of fard-1 and acl-7 in wild-type worms also partially impair lifespan extension promoted by phenformin (Figure 1—figure supplement 1B–C). This dependency is not confounded by chemical inhibition of reproduction, as lifespan analyses performed without the use of the thymidylate synthase inhibitor 5-fluoro-2′-deoxyuridine (FUdR) reveal similar abrogation of biguanide-mediated lifespan extension with inactivation of the ether lipid synthetic machinery (Figure 1—figure supplement 2A–F; Van Raamsdonk and Hekimi, 2011). Studies from this point forward are presented predominantly with phenformin because phenformin is more readily absorbed without need for a specific transporter, unlike metformin (Wu et al., 2016; Sogame et al., 2009; Segal et al., 2011), and our experience indicates more consistent lifespan extension with phenformin in C. elegans.

Genes responsible for ether lipid biosynthesis are necessary for biguanide-induced lifespan extension.
(A) C. elegans ether lipid synthesis is catalyzed by three enzymes: fatty acyl reductase FARD-1, acyltransferase ACL-7, and alkylglycerone phosphate synthase ADS-1 (adapted from Figure 1 of Shi et al., 2016 and Dean and Lodhi, 2018). The latter two are localized to the peroxisomal lumen. (B–D) Missense, loss-of-function mutations in fard-1 (B), acl-7 (C), and ads-1 (D) in C. elegans suppress phenformin-induced lifespan extension. (E–G) A deficiency of ether lipid synthesis in fard-1 (E), acl-7 (F), and ads-1 (G) worm mutants blunts metformin-induced lifespan extension. Results are representative of three biological replicates. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 by log-rank analysis. Note that (B–D) and (E–G) contain the same wild-type (wt) controls as they are visualized from the same replicate of the study. See also Figure 1—figure supplement 1 and refer to Supplementary file 1 for tabular survival data and biological replicates. (H–I) Normalized concentrations of phenformin (H) and metformin (I) in vehicle, 4.5 mM phenformin, or 50 mM metformin-treated wt C. elegans versus fard-1, acl-7, and ads-1 mutants. n=3 biological replicates; ***, p<0.004 by two-tailed Student’s t-test with Bonferroni correction for multiple hypothesis testing. Box represents 75th/25th percentiles, while whisker represents higher/lower hinge ± [1.5 * interquartile range (IQR)].
Because ether lipids are a major structural component of cell membranes, one possibility is that deficiencies in ether lipid synthesis compromises drug action by reducing biguanide bioavailability in the worm. To test this, we compared the relative levels of biguanides present in vehicle- and biguanide-treated wild-type animals to the three ether lipid synthesis mutants by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A comparison of normalized concentrations of phenformin across all four strains shows that phenformin abundance is quantitatively similar across wild-type and the three ether lipid mutant strains (Figure 1H and Figure 1—figure supplement 1D). Similar results were obtained when comparing levels of metformin in wild-type vs. ether lipid mutant animals (Figure 1I and Figure 1—figure supplement 1E). Thus, a deficiency in ether lipid synthesis does not significantly impact levels of biguanides in metformin- and phenformin-treated C. elegans.
Phenformin induces changes in ether lipid levels
We reasoned that if biguanides require ether lipid biosynthesis to promote lifespan extension, that phenformin may promote synthesis of one or more ether lipids. To investigate the impact of biguanides on ether lipids at a high level, we first utilized gas chromatography-mass spectrometry (GC-MS) analysis. We first recapitulated the observation that fard-1 mutants show absence of 18-carbon containing fatty alcohol derivatives (dimethylacetals [DMAs], which indicate alkenyl ether lipid or plasmalogen levels) and an accumulation of stearate (18:0) relative to wild-type controls by GC-MS (Figure 2A—B; Shi et al., 2016). We then asked if phenformin impacts the levels of 18-carbon alkenyl ether lipids in wild-type animals and if those corresponding changes are absent in fard-1 mutants. Strikingly, phenformin-treated wild-type worms display a significant increase in 18:0 DMA versus vehicle, whereas no such increase is evident in drug-treated fard-1 worms (Figure 2C). In addition, relative proportions of stearic acid (18:0) levels within the total fatty acid pool are significantly increased in fard-1 mutants treated with phenformin versus vehicle-treated fard-1 controls (Figure 2D). In comparison, the relative proportion of stearic acid does not rise in phenformin-treated wild-type animals, suggesting that stearate is being utilized for ether lipid production. Analysis of the total fatty acid pool by GC-MS (Figure 2—figure supplement 1) indicates that aside from several fatty acids (e.g. 18:2), the most pronounced differences were in the plasmalogen pool. In alignment, an assessment of levels of additional alkenyl fatty alcohols in phenformin-treated, wild-type animals indicates a parallel, significant increase in the less abundant 16:0 DMA and 18:1 DMA species (Figure 2E). We conclude that phenformin treatment leads to an overall increase of alkenyl ether lipid levels in C. elegans.

Phenformin treatment of C. elegans leads to increased abundance of multiple alkyl and alkenyl ether lipids.
(A–B) Loss-of-function fard-1 mutants have significant reduction in 18:0 fatty alcohols derivatized from 18-carbon containing alkenyl ether lipids (dimethylacetal [DMA]) by gas chromatography/mass spectrometry (GC/MS) (A) and accumulation of the saturated fatty acid stearate (18:0, B). (C) Wild-type (wt) worms treated with 4.5 mM phenformin display a significant increase in 18:0 DMA relative to vehicle control, indicative of higher levels of alkenyl ether lipids, with levels remaining essentially undetectable in fard-1 mutants on vehicle or drug. (D) Phenformin (4.5 mM) treatment does not impact stearate levels in wt worms, however it does result in a greater accumulation of stearate in fard-1 mutants. For (A–D), **, p<0.01; ****, p<0.0001, by t-test (A–B) or two-way ANOVA (C–D), n=3 biological replicates. (E) Phenformin (4.5 mM) treatment results in a significant increase in 16:0 DMA and 18:1 DMA in wt worms, relative to vehicle-treated controls *, p<0.05; **, p<0.01, by multiple t-tests, with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. n=3 biological replicates. (F) Heatmap of normalized ether lipid abundance following phenformin treatment in wt C. elegans indicates an overall increase in ether lipids relative to vehicle-treated controls, and this shift is absent in ether lipid deficient mutants. All metabolites shown have an FDR adjusted p<0.05 by one-way ANOVA followed by Fisher’s LSD post hoc testing for wt versus fard-1, ads-1, and acl-7 mutants. (G) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis shows that phosphatidylethanolamine-containing ether lipids detected exhibited a general trend toward increased abundance in wild-type worms treated with 4.5 mM phenformin. Four of these ether lipids reached statistical significance: PE(O-16:0/18:1), PE(O-18:0/18:3), PE(O-18:0/20:2), and PE(P-18:1/18:1). Eleven of the ether lipids detected are of the alkyl-type (indicated by ‘O’ in their name prior to fatty alcohol designation) whereas nine are of the alkenyl-type (plasmalogen, indicated by ‘P’ in their name prior to the fatty alcohol designation) ether lipids. For (G), *, p<0.05; **, p<0.01; ****, p<0.0001, by multiple t-tests, with multiple hypothesis testing correction by two-stage step-up method of Benjamini, Krieger, and Yekutieli, n=3 biological replicates. See Figure 2—source data 1 for raw and normalized mass spectrometry data.
-
Figure 2—source data 1
Excel file containing raw, normalized, and normalized and log10 transformed mass spectrometry data for phosphatidylethanolamine containing ether lipids detected by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Data from three biological replicates are shown for molecules indicated for vehicle or 4.5 mM phenformin treatment, for four different genetic backgrounds: wild-type animals (N2, wt), BX10 (ads-1 mutant), BX259 (acl-7 mutant), and BX275 (fard-1 mutant). Compound identity for each detected lipid as well as raw, normalized, or transformed mass counts on each of three tabs. Note, several of the lipids were not uniformly detected or of low abundance, and thus were filtered by the MetaboAnalyst parameters used and not represented on the ‘Normalized’ and ‘Normalized-Log10 Transformed’ tabs.
- https://cdn.elifesciences.org/articles/82210/elife-82210-fig2-data1-v1.xlsx
To investigate relative changes in individual ether lipid abundance in response to phenformin at high resolution, we utilized LC-MS/MS analysis. Using this method, we detected 20 alkyl and alkenyl phosphatidylethanolamine-based ether lipids previously noted to be the most abundant ether lipids in C. elegans (Drechsler et al., 2016; Shi et al., 2016; Figure 2F–G and Figure 2—source data 1). This analysis indicates that phenformin treatment results in a significant increase in normalized abundance of four ether lipids, PE(O-16:0/18:1), PE(O-18:0/18:3), PE(O-18:0/20:2), and PE(P-18:1/18:1), even when corrected for multiple hypothesis testing. Most ether lipids measured display mean levels that increase with phenformin treatment, though these changes are either nominally significant or exhibit a nonsignificant trend because of the strict threshold required to reach significance when correcting for multiple hypotheses. Finally, phosphatidylethanolamine ether lipid abundances were extremely low in fard-1, acl-7, and ads-1 mutants and unchanged by phenformin treatment, unlike in wild-type animals (Figure 2F and Figure 2—source data 1). In aggregate, these data indicate that phenformin treatment leads to increased abundance of multiple ether lipid species in C. elegans.
Peroxisomal ether lipid synthesis is essential to the biological action of phenformin
In order to begin to understand the governance of ether lipid biosynthesis by biguanides, we examined the expression of a C. elegans FARD-1::RFP translational reporter, under the control of its own promoter (Figure 2—figure supplement 2A). Exogenously expressed FARD-1 (fard-1 oe1) is expressed in the intestine and localizes near structures resembling lipid droplets by Nomarski microscopy (Figure 2—figure supplement 2B). Given that ether lipid biogenesis occurs between peroxisomes and the ER (Ghosh and Hajra, 1986; Hardeman and van den Bosch, 1989; Singh et al., 1993; Hua et al., 2017), we crossed this FARD-1::RFP reporter to an animal bearing a GFP reporter that illuminates peroxisomes in the intestine (GFP fused to a C-terminal peroxisomal targeting sequence 1 [PTS1]) to determine if localization of FARD-1 is regulated by biguanides. FARD-1 does not possess a predicted PTS, in contrast to ACL-7 and ADS-1. At baseline, FARD-1::RFP fluorescence partially overlaps with peroxisomally targeted GFP (Figure 2—figure supplement 2C). Colocalization analysis indicates that treatment with phenformin does not change the amount of overlap between FARD-1::RFP and GFP::PTS1 relative to vehicle-treated controls (Figure 2—figure supplement 2D). To confirm our earlier observation that suggests FARD-1 colocalization with lipid droplets, we used confocal imaging to assess the spatial distribution of an integrated FARD-1::RFP reporter (fard-1 oe3) in C. elegans fed C1-BODIPY-C12 to label lipid droplets (and treated with glo-4 RNAi to remove BODIPY-positive lysosome-related organelles) (Hermann et al., 2005; Zhang et al., 2010b; Zhang et al., 2010a). We found that FARD-1::RFP fluorescence directly surrounds some, but not all, BODIPY-positive lipid droplets in the worm intestine (Figure 2—figure supplement 2E). However, as with peroxisomes, phenformin does not alter the number of lipid droplets that are surrounded by FARD-1 or its distribution around lipid droplets (data not shown). Finally, FARD-1::RFP localizes into web-like structures in the fard-1(oe3) reporter that may represent smooth ER versus another cellular tubular vesicular network (Figure 2—figure supplement 2F), and this localization is also not altered by biguanide treatment. Thus, the regulation of ether lipid biosynthesis does not appear to be via differential localization of FARD-1.
We next examined expression of mRNAs encoding FARD-1, ACL-7, and ADS-1 following biguanide treatment. Each of these mRNAs decreased or remain unchanged in abundance upon treatment with biguanide via quantitative RT-PCR (Figure 2—figure supplement 2G–L), suggesting that ether lipids are not increased in phenformin treatment through a transcriptional mechanism. A parallel decrease in overall levels of FARD-1::RFP protein of fard-1(oe1) transgenics was seen with phenformin treatment (Figure 2—figure supplement 2M). These seemingly paradoxical data are likely consistent with post-translational negative feedback of ether lipids on the ether lipid biosynthetic pathway, as has been previously reported (Honsho et al., 2010).
To affirm that the peroxisome is an essential site of ether lipid production in biguanide action, we disrupted peroxisomal protein targeting and examined phenformin-stimulated lifespan extension. Indeed, either prx-5 or prx-19 RNAi impair lifespan extension prompted by phenformin fully or partially, respectively (Figure 3A–B). PRX-5 is involved in protein import into the peroxisomal matrix and PRX-19 is involved in proper sorting of proteins for peroxisomal biogenesis. Thus, either disruption of ether lipid biosynthetic machinery or of a principal site of ether lipid biosynthesis impairs phenformin’s pro-longevity benefit.

Peroxisomal protein import, fatty acid elongases, and fatty acid desaturases are required for the pro-longevity effects of biguanides.
(A–B) Knockdown of prx-5 (A) and prx-19 (B) by RNA interference (RNAi) eliminates or significantly suppresses phenformin-mediated lifespan extension. (C) Schematic representation of the mono- (MUFA) and polyunsaturated fatty acid (PUFA) synthesis pathway in C. elegans (adapted from Figure 1 of Watts, 2016). (D–G) RNAi of two fatty acid desaturases (D–E) and two fatty acid elongases (F and G) involved in the synthesis of 18- and 20-carbon PUFAs blunt phenformin-mediated lifespan extension in wild-type worms. Colored symbols for elo and fat genes (vs. those in black and white) in (C) indicates those that inhibit phenformin lifespan extension when knocked down by RNAi. For (A, B) and (D–G), results are representative of two to three biological replicates. **, p<0.01; ***, p<0.001; ****, p<0.0001 by log-rank analysis. Note that (D–G) contain the same wild-type controls as they are visualized from the same replicate of the study. See also Supplementary file 1 for tabular survival data and biological replicates.
Fatty acid elongases and desaturases are positive effectors of biguanide-mediated lifespan extension
Most mature ether lipid species contain a fatty acid in the sn-2 position linked by an ester bond (Dean and Lodhi, 2018). The majority of fatty acids conjugated in ether lipids are largely synthesized endogenously in C. elegans by fatty acid desaturases and fatty acid elongases (Perez and Van Gilst, 2008; Perez and Watts, 2021; Figure 3C). Thus, we hypothesized that some of these desaturases and elongases may also contribute mechanistically to biguanide-mediated lifespan extension. Indeed, RNAi knockdown of two fatty acid desaturases and two fatty acid elongases in phenformin-treated C. elegans blunted phenformin-stimulated lifespan extension relative to empty vector controls (Figure 3D–G). Notably, these four genes all contribute to the production of fatty acids 18–20 carbons in length with three or more double bonds. Although knockdown of fatty acid desaturases and elongases in C. elegans results in inherent lifespan extension on vehicle relative to wild-type controls on empty vector RNAi as has been previously reported (Shmookler Reis et al., 2011; Horikawa et al., 2008), RNAi knockdown of fat-3, fat-4, elo-1, and elo-2 mitigate phenformin-driven lifespan extension (Figure 3D–G). These results suggest the tantalizing possibility that specific fatty acid desaturases and elongases promote biguanide-mediated lifespan extension through contribution of long and polyunsaturated fatty acids (PUFAs) to the synthesis of ether lipids, though a mechanistically distinct role is also possible.
Genes involved in ether lipid biosynthesis are required in multiple longevity paradigms
Given the critical role of ether lipids in the response to biguanides, we hypothesized that these molecules may also play a broader role in diverse longevity paradigms involving metabolic or nutrient-sensing pathways. C. elegans mutant strains that exhibit (1) reduced mitochondrial function (isp-1), (2) disrupted mTORC1 signaling (raga-1), (3) abnormal pharyngeal pumping resulting in a dietary restricted-like state (eat-2), or (4) inhibition of insulin/insulin-like growth factor-1 signaling (daf-2), all result in extension of lifespan (Apfeld et al., 2004; Curtis et al., 2006; Senchuk et al., 2018; Schreiber et al., 2010). To determine whether requirement for the ether lipid biosynthetic machinery in aging generalizes to these other lifespan extension paradigms, we knocked down all three ether lipid biosynthetic enzymes by RNAi in wild-type C. elegans and four long-lived genetic mutants: raga-1, isp-1, eat-2, and daf-2. Knockdown of fard-1, acl-7, and ads-1 by RNAi results in suppression of lifespan extension in isp-1, raga-1, and eat-2 mutants (Figure 4A–C). However, knockdown of ether lipid synthesis genes by RNAi did not impact lifespan extension in daf-2 mutants (Figure 4—figure supplement 1). Thus, the ether lipid biosynthetic machinery plays a broad role in lifespan extension, and, importantly, does not non-selectively shorten lifespan by making animals generally unfit.

Genes involved in ether lipid biosynthesis are required for lifespan extension in multiple longevity paradigms.
(A–C) isp-1, raga-1, and eat-2 mutants display extended lifespan relative to wild-type animals that is dependent upon the three members of the ether lipid biosynthetic pathway. Results are representative of three biological replicates. **, p<0.01; ***, p<0.001; ****, p<0.0001 by log-rank analysis. See also Figure 4—figure supplement 1 and Supplementary file 1 for tabular survival data and biological replicates.
Overexpression of fard-1 is sufficient to promote lifespan extension
To determine whether stimulation of ether lipid biosynthesis is sufficient to prompt lifespan extension, we tested the effect of overexpression (oe) of the sole C. elegans fatty acid reductase that synthesizes fatty alcohols for ether lipid biogenesis, fard-1, on lifespan. Strikingly, fard-1(oe1) alone significantly extends lifespan (Figure 5A). This result is similar in a second, independent fard-1(oe2) transgenic line (Figure 5B). To confirm that fard-1(oe) lifespan extension is dependent upon ether lipid biosynthesis, we knocked down fard-1, acl-7, and ads-1 by RNAi in the fard-1(oe1) transgenic strain. As predicted, knockdown of three ether lipid biosynthetic enzymes leads to significant suppression of fard-1(oe1) lifespan extension (Figure 5C and Figure 5—figure supplement 1A–B).

fard-1 overexpression is sufficient to extend lifespan by modulating ether lipid synthesis.
(A–B) Two independently generated fard-1 overexpression (fard-1 oe1 and fard-1 oe2) transgenic strains exhibit lifespan extension that is not further extended by concomitant phenformin treatment. (C) RNA interference (RNAi) knockdown of ads-1 fully suppresses fard-1(oe1) lifespan extension, indicating that the fard-1(oe)-mediated lifespan extension is dependent upon ether lipid synthesis. (D) qRT-PCR analysis of wild-type and fard-1(oe3) animals treated with vehicle or phenformin until adult day 1 reveals that both biguanide treatment and fard-1 exogenous overexpression results in an equivalent reduction of native fard-1 gene expression, as indicated by primers targeting the native 3’ UTR of fard-1, a sequence not represented in the fard-1 overexpression transgene (n=3 biological replicates). (E–G) RNAi of skn-1 (E), aak-2 (F), and daf-16 (G) suppress fard-1(oe1)-mediated lifespan extension. For (A–C) and (E–G), results are representative of two to three biological replicates. *, p<0.05; ***, p<0.001; ****, p<0.0001 by log-rank analysis. Note that (F–G) contain the same wild-type controls as they are visualized from the same replicate of the study. See also Figure 4—figure supplement 1 and Supplementary file 1 for tabular survival data and biological replicates. **, p<0.01 by two-way ANOVA followed by Tukey’s multiple comparisons test. (H) Worms overexpressing a backcrossed, integrated FARD-1 (fard-1 oe3) display a significant increase in 16:0 and 18:1 but not 18:0 alkenyl ether lipids by gas chromatography/mass spectrometry (GC/MS). (I) Comparison of the total fatty acid pool indicates that the polyunsaturated fatty acids 20:4 arachidonic acid (ARA) and 20:5 eicosapentaenoic acid (EPA) are significantly increased in fard-1 overexpressing (fard-1 oe3) worms vs. wild-type animal, while several isomethyl (iso) and cyclopropyl (cyclo) fatty acids change in opposing directions. For (H–I), n=3 biological replicates. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 by multiple t-tests (with multiple hypothesis correction by two-stage step-up method of Benjamini, Krieger, and Yekutieli).
We observe that both phenformin treatment and fard-1 overexpression in fard-1(oe) animals non-additively reduce endogenous mRNA expression of fard-1 by ~40% (Figure 5D). This is consistent with our prior observation that mRNA levels of ads-1, acl-7, and fard-1 and protein levels of FARD-1 decrease following phenformin treatment (Figure 2—figure supplement 2G–M), and invokes end product negative feedback in the setting of stimulated ether lipid biogenesis, as previously observed in human and animal cellular models (Honsho et al., 2010).
To determine whether lifespan extension attributable to fard-1(oe) shares genetic dependencies with biguanide-mediated longevity, we independently knocked down skn-1/Nrf, aak-2/AMPK, and daf-16/FoxO by RNAi in a fard-1(oe) background. While skn-1/Nrf and aak-2/AMPK have previously been demonstrated to be necessary for metformin-stimulated lifespan extension, daf-16/FoxO has not (Onken and Driscoll, 2010; Kenyon et al., 1993). Lifespan extension attributable to fard-1(oe1) is suppressed by these three gene knockdowns (Figure 5E–G), indicating that it is mechanistically similar, but not identical, to biguanide-mediated lifespan extension (Cabreiro et al., 2013; Onken and Driscoll, 2010). In aggregate, these results support the notion that ether lipids are an important requirement in multiple, diverse longevity paradigms, and further that fard-1(oe) promotes mechanistically distinct lifespan extension in C. elegans.
To characterize shifts in ether lipids related to pro-longevity effects, we performed comparative GC-MS-based fatty acid profiling of our integrated fard-1(oe) animals. Levels of 16:0 and 18:1 alkenyl ether lipids (indicated by DMAs on GC-MS analysis) are significantly increased in fard-1(oe3) transgenic animals versus wild-type worms (Figure 5H). By comparison, 18:0 DMA ether lipids were not increased, indicating that the ether lipid pool has both similarities and differences between fard-1 overexpression and phenformin treatment. Echoing the analysis seen with phenformin treatment, few differences were found in a comparison of the relative abundance of fatty acids within the total lipid pool for fard-1(oe3) and wild-type worms (Figure 5I). Those exhibiting increases in fard-1(oe) include the PUFAs 20:4 arachidonate and 20:5 eicosapentaenoate. This suggests either that PUFAs play a mechanistic role in lifespan extension in fard-1(oe) or that they are increased because of longevity-promoting activity of ether lipids.
Ether lipids do not promote lifespan extension by modulating ferroptosis
Ether lipids have been reported to be protective against ferroptosis, an iron-dependent form of programmed cell death characterized by the accumulation of lipid peroxides (Zou et al., 2020; Perez et al., 2020). In order to determine whether ether lipids promote longevity downstream of biguanide action by modulating ferroptosis, we knocked down members of the glutathione peroxidase (GPX) family in animals overexpressing integrated fard-1 (fard-1 oe3 and fard-1 oe4), as has been previously reported to genetically facilitate lipid peroxidation and ferroptosis (Perez et al., 2020; Sakamoto et al., 2014; Figure 5—figure supplement 1C–E). This analysis indicates that gpx-1 (ortholog of human GPX4) RNAi leads to variable lifespan extension relative to wild-type controls and exhibits non-additive lifespan extension with fard-1(oe) (Figure 5—figure supplement 1C). Neither gpx-6 nor gpx-7 knockdown impacts lifespan extension in fard-1(oe) animals (Figure 5—figure supplement 1D–E). Further, GPX family RNAi do not negatively impact lifespan extension reproducibly downstream of phenformin (Figure 5—figure supplement 1F–H). We conclude that genetic triggers that induce ferroptosis do not impact phenformin-prompted or fard-1(oe) lifespan extension, and thus it is unlikely that either extend lifespan by suppressing ferroptosis.
The ether lipid biosynthetic machinery operates upstream of the stress responsive factor, skn-1/Nrf, to enable lifespan extension in response to biguanides
We noted when analyzing FARD-1 protein localization that somatic lipid droplets are generally less numerous in BODIPY-stained phenformin-treated animals vs. vehicle. Indeed, quantitative analysis indicates that intestinal lipid droplets are significantly less numerous following phenformin treatment (in glo-4 RNAi-treated FARD-1::RFP transgenics (fard-1 oe3) fed C1-BODIPY-C12 to label lipid droplets, Figure 6A). We previously reported that gain-of-function mutations in the nutrient- and stress-responsive transcription factor skn-1/Nrf prompt age-dependent, somatic depletion of fat (Asdf) (Lynn et al., 2015; Nhan et al., 2019). This, together with early adult decreases in lipid droplet numbers, suggested to us that phenformin may prompt longevity by activating metabolic stress defenses in an skn-1-dependent manner. Strikingly, we found that phenformin treatment produces Asdf at day 3 of adulthood, a phenotype that is quantitatively analogous to and non-additive with skn-1 gain-of-function mutants (Figure 6B–C). Compellingly, loss-of-function mutations in any of the three ether lipid biosynthetic genes completely prevent the phenformin-mediated Asdf phenotype (Figure 6B–C), suggesting that ether lipids mechanistically connect phenformin to promotion of skn-1-dependent pro-longevity metabolic defenses. As expected, fard-1 overexpressing animals also display an intermediate Asdf phenotype, with moderate enhancement by phenformin treatment (Figure 6B–C). Finally, the Asdf lipid shift evident with phenformin treatment requires skn-1, as biguanide-mediated lipid shifts are abrogated in skn-1 loss-of-function mutant animals (Figure 6D–E). In aggregate, these data indicate that ether lipids connect biguanides to activation of metabolic stress defenses and longevity downstream of SKN-1.

Phenformin modulates systemic lipid metabolism through an ether lipid-skn-1 signaling relay.
(A) The number of intestinal, C1-BODIPY-C12 labeled lipid droplets are significantly lower in day 1 adult phenformin-treated animals versus vehicle (FARD-1::RFP reporter transgenic [fard-1 oe3] worms are also treated with glo-4 RNA interference (RNAi) to remove BODIPY-positive lysosome-related organelles). n=2 biological replicates. *, p<0.05 by unpaired t-test. (B–C) Oil-red-O staining of day 3 adult phenformin-treated wild-type animals indicates that drug treatment leads to age-dependent somatic depletion of fat (Asdf), as previously reported for skn-1 gain-of-function mutants (skn-1 gf), suggesting that phenformin activates Asdf downstream of skn-1. Quantification (B) indicates that the proportion of Asdf animals is non-additively increased by phenformin treatment in an skn-1gf mutant, and that phenformin is no longer able to activate Asdf in three independent ether lipid deficient mutants (ads-1, acl-7, and fard-1). fard-1 overexpression results in an Asdf phenotype, moderately strengthened by phenformin treatment. For (B–C), n=3 biological replicates. (D–E) Oil-red-O staining of day 3 adult phenformin-treated wild-type and skn-1lf(zu135) animals reveals that the total loss of skn-1 function completely abrogates the phenformin-induced Asdf phenotype. Quantification (E) reveals that skn-1lf(zu135) decreases the proportion of Asdf animals relative to wild-type controls treated with phenformin. For (D–E), data represent n=3 biological replicates. (F) Phenformin treatment induces intestinal expression of dod-24, an established SKN-1 response target and innate immune effector, as indicated by increased dod-24p::GFP expression, in both OP50-1 and HT115 bacterial diets. RNAi knockdown of skn-1, fard-1, acl-7, and ads-1 all prevent significant phenformin-mediated induction of dod-24p::GFP. Quantification performed with at least 30 animals in each condition (10 animals assayed per replicate for 3 biologically independent experiments). ns, p>0.05; ****, p<0.0001 by two-way ANOVA followed by Tukey’s multiple comparisons test.
Our previous work determined that SKN-1 activates a metabolic stress defense response to drive somatic lipid depletion through enhancing lipid utilization and innate immunity gene expression that opposes canonical oxidative stress responses (Nhan et al., 2019). Concordant with the hypothesis that biguanides activate SKN-1 metabolic/innate immune and not oxidative stress defenses, phenformin treatment reduces expression of the canonical oxidative stress response gene gst-4 irrespective of bacterial diet source (Figure 6—figure supplement 1A–B), while reciprocally inducing expression of the innate immune response gene dod-24 in a manner dependent both upon skn-1 and ether lipids (Figure 6F and Figure 6—figure supplement 1C). Together with the observation that promotion of lifespan extension by both phenformin and fard-1(oe) require skn-1, these data suggest that biguanides activate an ether lipid-skn-1 signaling relay to drive longevity.
Biguanide-mediated ether lipid synthesis is necessary for a pro-longevity benefit irrespective of bacterial growth or metabolism
Previous studies into the biological action of metformin have suggested that biguanides mediate their lifespan-extending properties in the nematode through alterations in growth and metabolism of their bacterial food source (Cabreiro et al., 2013; Pryor et al., 2019). To evaluate whether biguanide effects on ether lipid synthesis are induced through a direct effect on the worm or via alterations in bacterial-host dynamics, we leveraged a robust, established methodology to chemically kill and metabolically inactivate the C. elegans OP50-1 food source prior to seeding on nematode growth media (NGM) plates (Beydoun et al., 2021). One percent paraformaldehyde (PFA) was identified as the lowest concentration in our hands that completely kills OP50-1 cultures prior to seeding, confirmed through bacterial titer analysis (Figure 6—figure supplement 2A). Analysis of wild-type adult day 1 nematodes treated with phenformin on live OP50-1 indicates that biguanide treatment significantly reduces somatic total fatty acid levels (Figure 6—figure supplement 2B–C), concordant with our staining data indicating phenformin prompts a low-fat, Asdf state (Figure 6). This result was preserved in wild-type animals grown on metabolically inactive PFA-treated OP50-1 as a food source, indicating that biguanides can significantly reduce somatic fatty acid levels irrespective of whether the bacterial food source is live vs. dead and metabolically inactive (Figure 6—figure supplement 2B–C). Notably, despite this significant reduction of overall fatty acids, biguanides preferentially protect levels of ether lipid-derived 16:0 DMA and 18:1 DMA, again irrespective of bacterial growth status (Figure 6—figure supplement 2D–E). Thus, we conclude that biguanides lead to relative increases in ether lipid levels through direct action in the nematode, rather than through indirect effects in the bacterial food source.
Based on the ability of biguanides to impact the lipid landscape via direct effects on the nematode, we then hypothesized that disruption of ether lipid biosynthesis may also abrogate biguanide-mediated lifespan extension irrespective of bacterial growth and metabolism. First, and in contrast to prior studies suggesting that lifespan requires drug effects on the Escherichia coli (Cabreiro et al., 2013; Pryor et al., 2019), we noted that under experimental conditions tested, metformin and phenformin both extend lifespan in wild-type animals whether grown on live or PFA-treated E. coli OP50-1 (Figure 6—figure supplement 3A–F). Consistent with the effect of biguanides on both lifespan and ether lipids being via direct action on the nematode, ads-1 deficiency completely blunts both metformin and phenformin-mediated lifespan extension irrespective of bacterial food source growth conditions (Figure 6—figure supplement 3A–F). In aggregate, these data suggest that biguanides increase proportions of ether lipids and require activated ether lipid machinery to exert pro-longevity benefits through direct drug action on the nematode.
Discussion
In an unbiased RNAi screen of ~1000 metabolic genes, we identified ether lipid biosynthesis as critical to the longevity-promoting and growth-inhibitory effects of metformin in C. elegans. Our results show that the biguanide phenformin promotes lifespan extension by stimulating biogenesis of ether lipids through direct action in the nematode, prompting longevity-promoting metabolic stress defenses mediated by skn-1. The broad importance of ether lipids is demonstrated by their requirement in multiple diverse paradigms of lifespan extension. Our findings also indicate that ether lipid modulation through overexpression of fard-1 is also sufficient to promote longevity. Thus, ether lipids form a heretofore unappreciated lynchpin of lifespan modulation and are sufficient to support healthy aging through multiple central longevity effectors, including skn-1.
Differences in ether lipid abundance and composition are correlated with diseases of aging. The uniform lethality associated with human genetic ether lipid deficiency, as in the case of patients diagnosed with RCDP and Zellweger syndrome, has made it difficult to study the role of ether lipids in aging and aging-associated diseases (Braverman et al., 1997; Motley et al., 1997; Purdue et al., 1997; Itzkovitz et al., 2012). Nonetheless, observational studies demonstrate decreases in certain plasmalogen species in Alzheimer’s disease, suggesting a probable link between ether lipids and aging-related pathologies (Grimm et al., 2011; Goodenowe et al., 2007; Han et al., 2001). Ether lipids have conflicting roles in cancer; while loss of the ether lipid biosynthetic machinery profits cancer cell survival by enhancing resistance to ferroptosis (Zou et al., 2020), in other contexts, ether lipid deficiency results in impaired pathogenicity in various human cancer cells (Benjamin et al., 2013; Perez et al., 2020). Cancer cells generally have higher levels of ether lipids compared to normal cells, leading others to suggest that ether lipids confer pro-survival benefit (Benjamin et al., 2013; Albert and Anderson, 1977; Snyder and Wood, 1969). However, certain ether lipid species have also been reported to have anti-tumor properties (Jaffrès et al., 2016; Arthur and Bittman, 2014). Thus, in line with the results we present here, it is critical to understand ether lipids in context. Future work will need to focus on the impact of specific ether lipid species rather than the whole class en masse to understand which may play a beneficial versus detrimental role in health.
Studies in long-lived animal models suggest that there is an association between ether lipid content and animal longevity, such as in the naked mole-rat (Heterocephalus glaber) (Mitchell et al., 2007) and the mud clam Arctica islandica (Munro and Blier, 2012). Higher plasmalogen levels in naked mole-rat tissues versus mice are speculated to contribute to protection of cellular membranes via a reduction of oxidative stress (Mitchell et al., 2007). Similarly, exceptionally long-lived humans harbor higher levels of phosphatidylcholine-derived, short chained alkyl ether lipids and a lower levels of phosphatidylethanolamine-derived longer chained plasmalogens (Pradas et al., 2019), but these associations are of unclear functional significance. Although it is clear from work presented here that ether lipid deficiency in C. elegans prevents longevity downstream of mitochondrial electron transport chain dysfunction, mTOR deficiency, caloric restriction, and biguanides alike, the precise lipid(s) conferring this activity remains unknown. Each of these longevity paradigms has features of nutrient deficiency, energy stress, or nutrient sensing, so it is possible that ether lipids are at least part of the common effector arm conferring benefit in aging to various forms of metabolic stress. It is particularly interesting that daf-2 loss-of-function does not require ether lipid biosynthetic machinery and yet has a clear requirement for skn-1. These observations suggest the very likely possibilities that (1) it is possible to activate skn-1 through multiple, parallel mechanisms, only some of which require ether lipids and (2) that there are multiple modes of skn-1 activation that promote longevity, each of which has distinct transcriptional programs (Nhan et al., 2019; Castillo-Quan et al., 2023).
Our results suggest that unsaturated fatty acids and phosphatidylethanolamine ether lipids are essential to the health-promoting effects of biguanides. Although we see major shifts in abundance of alkenyl ether lipids, evidence of the necessity of specific ether lipids in biguanide-induced longevity and for promoting healthy aging awaits the ability to modulate the level of specific ether lipids. Additionally, disruption of ether lipid biosynthesis has been shown to increase the proportion of stearate (18:0) and other saturated fatty acids (Shi et al., 2016). Thus, at this time, we cannot rule out the possibility that biguanide-stimulated alterations in ether lipid biosynthesis serves to divert accumulation of lipid species that are detrimental to lifespan, for instance, saturated fatty acids. Nonetheless, considering our finding that ether lipids prompt metabolic stress defenses, this alternative mechanism is less likely. Definitive proof will require a deeper understanding of the regulation of specific steps dictating the synthesis and modification of ether lipids of different fatty alcohol and fatty acid composition.
Based upon our findings, ether lipid synthesis is likely to be regulated post-translationally by biguanide treatment. The demonstrated increases in plasmalogens and specific ether lipids are both consistent with increases in activity of the ether lipid biosynthetic machinery. While we do not understand the mechanism for the increased activity of ether lipid synthesizing enzymes, the decreases in mRNAs for acl-7, ads-1, and fard-1 prompted by phenformin treatment and by overexpression of fard-1 alike invoke negative feedback of the end product(s) of ether lipid biogenesis on transcription of genes encoding ether lipid biosynthetic enzymes. It should be noted that this possibility is consistent with previous work showing that higher levels of ether lipids promote proteasomal degradation of peroxisomal Far1 protein (Honsho et al., 2010). Colocalization of the fatty alcohol reductase, FARD-1, with both peroxisomes and lipid droplets is similarly not impacted by biguanides. We cannot rule out the possibility, however, that the exogenous, overexpressed nature of FARD-1::RFP in these experiments may result in a hyperactivated ether lipid biosynthesis state, thereby locking FARD-1::RFP localization in an activated configuration that cannot be further induced with biguanide treatment. Future studies leveraging endogenously tagged FARD-1 animals will be required to resolve this caveat. Finally, further investigation into the precise molecular interactions between FARD-1 protein and other organelles will be required to further understand how FARD-1 and the other ether lipid biosynthetic enzymes are regulated by biguanides and in aging.
Strikingly, our data demonstrate for the first time that ether lipids are required for phenformin to activate metabolic defenses downstream of the stress- and metabolism-responsive transcription factor skn-1/Nrf. Phenformin drives age-dependent somatic depletion of fat (Asdf), a phenotype we previously reported upon genetic activation of skn-1 (Lynn et al., 2015; Nhan et al., 2019). Based upon our own work, biguanides do not stimulate canonical skn-1 antioxidant defenses such as gst-4 expression, in contrast to the subtle effects seen in the existing literature (Cabreiro et al., 2013; Onken and Driscoll, 2010). Indeed, we observe a significant decrease in gst-4 expression with phenformin treatment, reciprocally balanced by increased innate immune dod-24 expression in a manner dependent upon skn-1 and the ether lipid machinery. We suggest that skn-1 is uniquely required for metabolic stress defenses downstream of metformin such as Asdf, rather than canonical oxidative or proteostatic defenses. Thus, the requirement for ether lipids in Asdf activation by phenformin confirm that this class of lipids plays a heretofore unappreciated role in a distinct form of skn-1 activation mimicked by genetic forms of skn-1 activation that we have previously reported (Lynn et al., 2015; Nhan et al., 2019).
Lifespan extension resulting from overexpression of fard-1 shows mechanistic similarities and dissimilarities from biguanide action in longevity. Curiously, and concordant with the idea that ether lipids participate in the activation of skn-1, fard-1 overexpression requires intact skn-1 and AMPK action. Discordantly, biguanides do not require daf-16/FoxO, but fard-1 overexpression does. There are many possible explanations for this. It could be that fard-1 overexpression alters the ether lipid landscape in a manner not analogous to biguanide treatment, either in distinct tissues or with regard to different ether lipid molecular species, and that these differences have distinct molecular effectors. Second, the degree of ether lipid alteration may be different following biguanide treatment vs. fard-1 overexpression. We have not explored whether overexpression of acl-7 and/or ads-1 similarly extend lifespan. Further work will be needed to determine the lifespan benefit attributable to augmentation of peroxisomal acl-7 or ads-1 activity, and whether any benefit is mechanistically similar to fard-1 overexpression. Finally, it is highly likely based upon the myriad potential direct and indirect sites of action of biguanides in aging, including but not limited to mitochondria, lysosomes, the nuclear pore complex, mTOR, and AMPK that distinct effector mechanisms are required by biguanides versus fard-1 overexpression (Cabreiro et al., 2013; Wu et al., 2016; Chen et al., 2017; Pryor et al., 2019; Ma et al., 2022; Wheaton et al., 2014; Onken and Driscoll, 2010; Espada et al., 2020). In spite of the complexity of the biological responses to ether lipids, an opportunity lies ahead: further study of ether lipid roles in aging can provide insights into the full spectrum of signals that favorably impact positive effectors of longevity.
In aggregate, data presented here indicate that ether lipid biosynthesis plays a broader role in aging than previously described. The necessity of the ether lipid machinery in metformin- and phenformin-stimulated lifespan extension and in multiple longevity paradigms indicates that ether lipids serve as a lynchpin through which lifespan is modulated (Figure 7A–B). Our demonstration that overexpression of fard-1 alone results in lifespan extension provides an exciting opportunity to identify ether lipids that promote health and the effector mechanisms through which they act. Finally, these results support the exciting possibility that modulation of ether lipids pharmacologically or even dietarily may provide a new potential therapeutic target in aging and aging-related diseases.

Schematic representation for the role of the ether lipid biosynthetic machinery in multiple pro-longevity paradigms.
(A) Model of ether lipid action in biguanide-prompted lifespan extension. Activation of ether lipid biosynthesis leads to longevity-promoting activity of metabolic stress defenses downstream of the transcription factor skn-1. (B) Model portraying a broader than previously appreciated role of ether lipids in longevity downstream of biguanides, mitochondrial electron transport inhibition, mTORC1 inhibition, and eat-2 mutation-mediated dietary restriction (EAT-2 DR). Dashed lines for DAF-16 indicate its requirement for fard-1 overexpression-, but not biguanide-mediated lifespan extension, suggesting a context-dependent role for daf-16/FoxO in mediating pro-longevity outcomes through modulation of ether lipid levels.
Materials and methods
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Strain, strain background (Escherichia coli) | OP50-1 | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00041971 | Standard laboratory stock |
Strain, strain background (Escherichia coli) | HT115(DE3) | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00041079 | Background strain for RNAi clones utilized from Ahringer and Vidal Libraries |
Strain, strain background (Caenorhabditis elegans) | Bristol N2 (wt) | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00000001 | Standard laboratory wild-type strain |
Strain, strain background (Caenorhabditis elegans) | fard-1(wa28) [G261D] | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00004025 | BX275 |
Strain, strain background (Caenorhabditis elegans) | acl-7(wa20) [R234C] | Caenorhabditis Genetics Center | RRID: WS-STRAIN:WBStrain00004024 | BX259 |
Strain, strain background (Caenorhabditis elegans) | ads-1(wa3) [G454D] | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00004007 | BX10 |
Strain, strain background (Caenorhabditis elegans) | daf-2(e1370) | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00004309 | CB1370 |
Strain, strain background (Caenorhabditis elegans) | isp-1(qm150) | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00026672 | MQ989 |
Strain, strain background (Caenorhabditis elegans) | raga-1(ok701) | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00035849 | VC533 |
Strain, strain background (Caenorhabditis elegans) | eat-2(da465) | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00005463 | DA465 |
Strain, strain background (Caenorhabditis elegans) | mgIs43[ges-1p::GFP::PTS1] | Soukas Laboratory | N/A | MGH48 |
Strain, strain background (Caenorhabditis elegans) | skn-1(lax188) | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00034420 | skn-1gf, SPC168 |
Strain, strain background (Caenorhabditis elegans) | agIs6[dod-24p::GFP] | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00004921 | CF3556 |
Strain, strain background (Caenorhabditis elegans) | dvIs19[(pAF15)gst-4p::GFP::NLS] | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00005102 | CL2166 |
Strain, strain background (Caenorhabditis elegans) | skn-1(zu135) | Caenorhabditis Genetics Center | RRID: WB-STRAIN:WBStrain00007251 | skn-1lf, EU31 |
Genetic reagent (Caenorhabditis elegans) | alxEx122[fard-1p::FARD-1::mRFP::HA unc-54 3'UTR myo-2p::GFP] | This study | MGH471 | fard-1 (oe1) |
Genetic reagent (Caenorhabditis elegans) | alxEx135[fard-1p::FARD-1::mRFP::HA unc-54 3'UTR myo-2p::GFP] | This study | MGH472 | fard-1 (oe2) |
Genetic reagent (Caenorhabditis elegans) | alxIs45[fard-1p::FARD-1::mRFP::HA::unc-54 3'UTR myo-2p::GFP] | This study | MGH605 | fard-1 (oe3), backcrossed into N2 8× |
Genetic reagent (Caenorhabditis elegans) | alxIs46[fard-1p::FARD-1::mRFP::HA::unc-54 3’UTR myo-2p::GFP] | This study | MGH606 | fard-1 (oe4), backcrossed into N2 8× |
Genetic reagent (Caenorhabditis elegans) | mgIs43[ges-1p::GFP::PTS1]; alxEx122[fard-1p::FARD-1::mRFP::HA::unc-54 3’UTR myo-2p::GFP] | This study | MGH607 | GFP::PTS1; FARD-1::RFP, prepared by crossing MGH48 into MGH471 |
Sequence-based reagent | 5’-TGCATGCCTGCAGGTCGACTTTGACAAAAGTTCTGTTGCCG-3’ | This study | AS-4524 | Forward primer used to generate fard-1 overexpression construct |
Sequence-based reagent | 5’-TTTGGGTCCTTTGGCCAATCGCTTTTTTGAAGATACCGAGAATAATCC-3’ | This study | AS-4527 | Reverse primer used to generate fard-1 overexpression construct |
Sequence-based reagent | 5’-TGCTGATCGTATGCAGAAGG-3’ | This study | act-1 F | qRT-PCR Primer |
Sequence-based reagent | 5’-TAGATCCTCCGATCCAGACG-3’ | This study | act-1 R | qRT-PCR Primer |
Sequence-based reagent | 5’-GTTCCCGTGTTCATCACTCAT-3’ | This study | pmp-3 F | qRT-PCR Primer |
Sequence-based reagent | 5’-ACACCGTCGAGAAGCTGTAGA-3’ | This study | pmp-3 R | qRT-PCR Primer |
Sequence-based reagent | 5’-ACAAGTCACCAATGGCTCCAC-3’ | This study | fard-1 F | qRT-PCR Primer |
Sequence-based reagent | 5’-GCTTTGGTCAGAGTGTAGGTG-3’ | This study | fard-1 R | qRT-PCR Primer |
Sequence-based reagent | 5’-cgatagtgtgtctgttgattgtga-3’ | This study | fard-1 F (Native 3’ UTR) | qRT-PCR Primer |
Sequence-based reagent | 5’-agttattgttgatgagagagtgcg-3’ | This study | fard-1 R (Native 3’ UTR) | qRT-PCR Primer |
Sequence-based reagent | 5’-GTTTATGGCTGGCGTGTTG-3’ | This study | acl-7 F | qRT-PCR Primer |
Sequence-based reagent | 5’-CGGAGAAGACAGCCCAGTAG-3’ | This study | acl-7 R | qRT-PCR Primer |
Sequence-based reagent | 5’-GCGATTAACAAGGACGGACA-3’ | This study | ads-1 F | qRT-PCR Primer |
Sequence-based reagent | 5’-CGATGCCCAAGTAGTTCTCG-3’ | This study | ads-1 R | qRT-PCR Primer |
Chemical compound, drug | C1-BODIPY-C12 (green) | Invitrogen | Cat#D-3823 | N/A |
Chemical compound, drug | 5-fluoro-2′-deoxyuridine (FUdR) | Fisher Scientific | Cat#F10705 | N/A |
Chemical compound, drug | Metformin hydrochloride | MilliporeSigma | Cat#PHR1084 | N/A |
Chemical compound, drug | Phenformin hydrochloride | MilliporeSigma | Cat#PHR1573 | N/A |
Commercial assay or kit | Quantitect Reverse Transcription Kit | QIAGEN | Cat#205314 | N/A |
Commercial assay or kit | Quantitect SYBR Green PCR Reagent | QIAGEN | Cat#204145 | N/A |
Chemical compound, drug | Levamisole | MilliporeSigma | Cat#L9756 | N/A |
Software, algorithm | OASIS2 | Structural Bioinformatics Laboratory, POSTECH | https://sbi.postech.ac.kr/oasis2/surv/ | N/A |
Software, algorithm | MetaMorph | Molecular Devices | https://www.moleculardevices.com/products/cellular-imaging-systems/acquisition-and-analysis-software/metamorph-microscopy | N/A |
Software, algorithm | Xcalibur (v4.1.31.9) | Thermo Fisher Scientific | Cat#OPTON-30965 | N/A |
Software, algorithm | QualBrowser (v4.1.31.9) | Thermo Fisher Scientific | Cat#XCALI-97617 | N/A |
Software, algorithm | MZmine (v2.36) | Open Source | RRID: SCR_012040, http://mzmine.github.io | N/A |
Software, algorithm | MetaboAnalyst (v5.0) | N/A | https://www.metaboanalyst.ca | N/A |
Software, algorithm | CellProfiler (v4.2.1) | Broad Institute | https://cellprofiler.org | N/A |
Software, algorithm | Prism (v9.0) | GraphPad by Dotmatics | https://www.graphpad.com/ | N/A |
Software, algorithm | Fiji/ImageJ2 (v2.13.1) | NIH | https://imagej.net/software/fiji/ | N/A |
C. elegans genetics
Request a detailed protocolStrains were maintained at 20°C grown on E. coli OP50-1 (RRID: WB-STRAIN:WBStrain00041971) for all experiments unless otherwise indicated. The following strains were used in this study: N2 (wt, wild-type strain, RRID: WB-STRAIN:WBStrain00000001), BX275 fard-1(wa28) [G261D] (RRID: WB-STRAIN:WBStrain00004025), BX259 acl-7(wa20) [R234C] (RRID: WS-STRAIN:WBStrain00004024), BX10 ads-1(wa3) [G454D] (RRID: WB-STRAIN:WBStrain00004007), CB1370 daf-2(e1370) (RRID: WB-STRAIN:WBStrain00004309), MQ989 isp-1(qm150) (RRID: WB-STRAIN:WBStrain00026672), VC533 raga-1(ok701) (RRID: WB-STRAIN:WBStrain00035849), DA465 eat-2(da465) (RRID: WB-STRAIN:WBStrain00005463), MGH48 mgIs43[ges-1p::GFP::PTS1], SPC168 skn-1(lax188) (skn-1gf, RRID: WB-STRAIN:WBStrain00034420), CF3556 agIs6[dod-24p::GFP] (RRID:WB-STRAIN:WBStrain00004921), CL2166 dvIs19 [(pAF15)gst-4p::GFP::NLS] (RRID:WB-STRAIN:WBStrain00005102), and EU31 skn-1(zu135) (skn-1lf, RRID: WB-STRAIN:WBStrain00007251). BX275, BX259, and BX10 strains contain missense mutations that result in loss-of-function of the ether lipid biosynthesis, as previously described (Shi et al., 2016). For fard-1 overexpression, the following strains were generated: MGH471 alxEx122[fard-1p::FARD-1::mRFP::HA unc-54 3'UTR myo-2p::GFP] (fard-1 oe1), MGH472 alxEx135[fard-1p::FARD-1::mRFP::HA unc-54 3'UTR myo-2p::GFP] (fard-1 oe2), MGH605 alxIs45[fard-1p::FARD-1::mRFP::HA::unc-54 3'UTR myo-2p::GFP] (fard-1 oe3), and MGH606 alxIs46[fard-1p::FARD-1::mRFP::HA::unc-54 3’UTR myo-2p::GFP] (fard-1 oe4). All strains for fard-1 overexpression were backcrossed 8× to wild-type N2 Bristol. For colocalization analysis with peroxisomally targeted GFP, we crossed MGH48 and MGH471 to generate the strain: MGH607 mgIs43[ges-1p::GFP::PTS1]; alxEx122[fard-1p::FARD-1::mRFP::HA::unc-54 3’UTR myo-2p::GFP] (noted in text as GFP::PTS1; FARD-1::RFP).
Generation of fard-1 C. elegans transgenic lines
Request a detailed protocolFor FARD-1 expression, the entire genomic sequence of the fard-1 locus (3659 bp), including introns and exons, plus 4910 bp of promoter were amplified and cloned into a modified Fire vector driving fard-1 fused to mRFP and an HA epitope tag at the C-terminus. The following cloning primers were used:
F: 5’-TGCATGCCTGCAGGTCGACTTTGACAAAAGTTCTGTTGCCG-3’ and
R: 5’-TTTGGGTCCTTTGGCCAATCGCTTTTTTGAAGATACCGAGAATAATCC-3’.
The fard-1 overexpression construct was injected at 10 ng/μL (alxEx122) and 18 ng/μL (alxEx135) into the gonad of wild-type adult animals with salmon sperm DNA as a carrier and 1.5 ng/μL myo-2p::GFP as a co-injection marker. alxEx122 was subsequently integrated by UV irradiation and 8× backcrossed to wild-type N2 Bristol to obtain MGH605 and MGH606.
RNAi assays
Request a detailed protocolRNAi clones were isolated from a genome-wide E. coli RNAi library (generated in strain HT115(DE3), RRID: WB-STRAIN:WBStrain00041079), sequence verified, and fed to animals as described (Kamath and Ahringer, 2003). RNAi feeding plates (6 cm) were prepared using a standard NGM recipe with 5 mM isopropyl-β-D-thiogalactopyranoside and 200 μg/mL carbenicillin. RNAi clones were grown for 15 hr in Luria Broth (LB) containing 100 μg/mL carbenicillin with shaking at 37°C. The stationary phase culture was then collected, concentrated through centrifugation, the supernatant was discarded, and the pellet was resuspended in LB to 20% of the original culture volume; 250 μL of each RNAi clone concentrate was added to RNAi plates and allowed to dry at least 24 hr prior to adding biguanide. Drug treatment was added to seeded RNAi plates and allowed to dry at least 3 hr before adding worms.
Longevity assays
Request a detailed protocolLifespan analysis was conducted at 20°C, as previously described (Soukas et al., 2009). Briefly, synchronized L1 animals were seeded onto NGM (for mutant treatment) or RNAi plates (for RNAi) and allowed to grow until the L4 to YA transition stage. On day 0 of adulthood as indexed in the figure legend, ~50–60 L4/YA worms per plate (unless otherwise noted) were transferred onto fresh NGM or RNAi plates. These NGM and RNAi plates were supplemented with 30 μM and 100 μM FUdR to suppress progeny production, respectively. For biguanide treatment, about ~55–60 synchronized L1 animals (unless otherwise noted) were seeded onto plates containing 50 mM metformin or 4.5 mM phenformin. Based upon power calculations for log-rank analysis, minimum N of 50 (per group) was chosen to satisfy α=0.05, β=0.2, and effect size = 20% difference in lifespan (Petrascheck and Miller, 2017). At the L4/YA stage, these worms were transferred to plates containing biguanide treatment and FUdR for the remainder of their life. For experiments performed without the use of FUdR, animals were transferred to freshly seeded RNAi and drug supplemented plates every 2 days between day 0 and day 10 of adulthood, ensuring no crossover contamination of progeny or laid eggs on the lifespan plates until the animals cease the reproductive stage. Dead worms were counted every other day, and scoring investigators were blinded as to the experimental group/treatment until the conclusion of each experiment. All lifespans performed include same-day N2 wild-type (wt) controls examined simultaneously with experimental test animals in each study. Statistical analysis was performed with online OASIS2 resources (Han et al., 2016).
Body size determination of C. elegans
Request a detailed protocolWe measured worm body size in response to biguanide treatment by imaging as previously described (Wu et al., 2016). Egg prep synchronized wild-type worms were treated with empty vector (L4440) or ether lipid biosynthesis machinery RNAi and treated with vehicle (ddH2O) or 160 mM metformin. After ~65–70 hr, worms were transferred into a 96-well plate, washed 3× with M9, and paralyzed in M9 buffer with 1 mg/mL levamisole (L9756-10G, Sigma-Aldrich). Once immobilized, brightfield imaging was performed at ×5 magnification on a Leica DM6000 microscope within 5 min of transferring to a 96-well Teflon imaging slide. We determined the maximal, longitudinal cross-sectional area of the imaged worms by using MetaMorph software for a minimum of ~80 animals per condition in each experiment. Results of a single experiment are shown. Each experiment was performed at least twice, and results were consistent between experiments.
GC/MS lipidomics
Request a detailed protocolLipid extraction and GC/MS of extracted, acid-methanol-derivatized lipids was performed as described previously (Pino and Soukas, 2020; Pino et al., 2013). Briefly, 5000 synchronous mid-L4 animals were sonicated with a probe sonicator on high intensity in a microfuge tube in 100–250 µL total volume. Following sonication, lipids were extracted in 3:1 methanol:methylene chloride following the addition of acetyl chloride in sealed borosilicate glass tubes, which were then incubated in a 75°C water bath for 1 hr. Derivatized fatty acids and fatty alcohols were neutralized with 7% potassium carbonate, extracted with hexane, and washed with acetonitrile prior to evaporation under nitrogen. Lipids were resuspended in 200 µL of hexane and analyzed on an Agilent GC/MS equipped with a Supelcowax-10 column as previously described (Pino and Soukas, 2020). Fatty acids and alcohols are indicated as the normalized peak area of the total of derivatized fatty acids and alcohols detected in the sample. Based upon power calculation for pairwise comparison, a minimum n of 3 biological replicates (per group) was chosen to satisfy α=0.05, β=0.2, and effect size = 50% with σ=20%. Analyses were blinded to the investigator conducting the experiment and mass spectrometry calculations until the conclusion of each experiment when aggregate statistics were computed.
LC/MS-MS lipidomics
Request a detailed protocolWild-type, fard-1, acl-7, and ads-1 worm mutants were collected using conditions that enabled our reported longevity phenotypes. Briefly, collection for LC/MS-MS processing comprised of three replicates of these four strains that were independently treated with vehicle (ddH2O) and 4.5 mM phenformin on 10 cm NGM plates. Based upon power calculations, as for GC/MS, a minimum n of 3 biological replicates (per group) was chosen to satisfy α=0.05, β=0.2, and effect size = 50% with σ=20%, though the power is only expected to hold for the first significant difference detected. Analyses were blinded to the investigator conducting the experiment and mass spectrometry calculations until the conclusion of each experiment when aggregate statistics were computed. A total of ~6000 animals (2×10 cm plates, 3000 worms per plate) were utilized per sample. These worms were washed with M9 (4×), concentrated into 200 μL of M9, and then flash frozen with liquid nitrogen in 1.5 mL Eppendorf microcentrifuge tubes. Worm pellets were transferred to 2 mL impact resistant homogenization tubes containing 300 mg of 1 mm zirconium beads and 1 mL of 90:10 ethanol:water. Using a Precellys 24 tissue homogenizer, samples were homogenized in three 10 s cycles at 6400 Hz followed by 2 min of sonication. Samples were then placed at –20°C for 1 hr to facilitate protein precipitation. Samples were transferred to 1.5 mL microfuge tubes and centrifuged at 14,000 × g for 10 min at 4°C. After centrifugation, 120 μL of supernatant was dried in vacuo and resuspended in 120 μL of 80:20 methanol:water containing internal standards 1 ng/μL CUDA and 1 ng/μL MAPCHO-12-d38. Lipidomic data was acquired by injecting 20 μL of sample onto a Phenomenex Kinetex F5 2.6 μm (2.1×100 mm) column at 40°C and flowing at 0.35 mL/min. Metabolites were eluted using (A) water containing 0.1% formic acid and (B) acetonitrile:isopropanol (50:50) containing 0.1% formic acid using the following gradient: 0% B from 0 to 1 min, 0–50% B from 1 to 6 min, 50–100% B from 6 to 17 min, and 100% B hold from 17 to 20 min. Compounds were detected using a Thermo Scientific QExactive Orbitrap mass spectrometer equipped with a heated electrospray ionization source operating in positive and negative ion mode with the following source parameters: sheath gas flow of 40 units, aux gas flow of 15 units, sweep gas flow of 2 units, spray voltage of ±3.5 kV, capillary temperature of 265°C, aux gas temp of 350°C, S-lens RF at 45. Data was collected using an MS1 scan event followed by four DDA scan events using an isolation window of 1.0 m/z and a normalized collision energy of 30 arbitrary units. For MS1 scan events, scan range of m/z 100–1500, mass resolution of 17.5K, AGC of 1e6 and inject time of 50 ms was used. For tandem MS acquisition, mass resolution of 17.5K, AGC 5e5 and inject time of 80 ms was used. Data was collected using Thermo Xcalibur software (version 4.1.31.9) and analyzed using Thermo QualBrowser (version 4.1.31.9) as well as MZmine 2.36.
Statistical analysis of metabolomics data
Request a detailed protocolAll visualization and significance testing of metabolomics was conducted using the MetaboAnalyst 5.0 package (Pang et al., 2021). Mass integration values for 9192 compounds were extracted from full-scan LC-MS/MS measurements of L4 to young adult (YA) transition wild-type (N2 Bristol), ads-1(wa3), acl-7(wa20), and fard-1(wa28) animals treated from L1 hatch with vehicle, 4.5 mM phenformin, or 50 mM metformin. Missing and zero values in the data matrix were imputed via replacement with 1/5th of the minimum positive value for each variable. Abundance values were subsequently filtered based on interquartile range (reducing the compound list to the 2500 most variable compounds), and log10 transformed. Quantile normalization was then performed, followed with division by the standard deviation of each variable (auto-scaling). Normalized abundance values for each metabolite were then extracted based upon MS/MS signatures for phosphatidylethanolamine ether lipids and assessed for statistical significance via one-way ANOVA followed by false discovery rate (FDR) control using the Benjamini-Hochberg method (Benjamini and Hochberg, 1995). Post hoc testing was then performed using Fisher’s LSD to evaluate pairwise comparison significance. Metabolites were considered differentially abundant in any one condition with an FDR controlled p-value <0.05. The top 25 metabolites across treatment (ranked by ANOVA f statistic and FDR value) were visualized using a heatmap of Euclidean distance measurements, with Ward clustering of samples and normalized compound abundances included. All mass integration values for identified phosphatidylethanolamine containing ether lipids, normalized abundance values, and log-transformed, normalized abundance values are included in this manuscript as Figure 2—source data 1. These same data have been made publicly available and can be found at Dryad.
Quantitative RT-PCR
Request a detailed protocolTo assess changes in mRNA levels of fard-1, acl-7, and ads-1 in response to biguanide treatment, we used quantitative RT-PCR as previously described (Wu et al., 2016). Briefly, synchronized wild-type N2 (wt) or fard-1 (oe3) L1 animals were seeded onto OP50-1 NGM plates containing vehicle (ddH2O), 50 mM metformin, or 4.5 mM phenformin. ~1600 worms were collected from four 6 cm plates per replicate, per condition (with no more than 400 worms seeded per plate to prevent overcrowding). n=3 biological replicates. Worms were collected at the L4 to YA transition (for wild-type analysis) or at adult day 1 (for fard-1 (oe3) analysis) using M9 buffer and washed an additional 3×, allowing worms to settle by gravity between washes. Total RNA was extracted using TRIzol and phenol-chloroform extraction. Reverse transcription was performed with the Quantitect Reverse Transcription kit (QIAGEN). qRT-PCR was conducted in triplicate using Quantitect SYBR Green PCR reagent (QIAGEN) following the manufacturer’s instructions on a Bio-Rad CFX96 Real-Time PCR system (Bio-Rad). If not processed immediately, worms were flash frozen in liquid nitrogen and kept in −80°C until RNA preparation. The sequences for primer sets used in C. elegans are:
act-1:
F: 5’-TGCTGATCGTATGCAGAAGG-3’ and
R: 5’-TAGATCCTCCGATCCAGACG-3’
pmp-3:
F: 5’-GTTCCCGTGTTCATCACTCAT-3’ and
R: 5’-ACACCGTCGAGAAGCTGTAGA-3’
fard-1 (spanning Exons 5–6, Figure 2—figure supplement 2G and J) :
F: 5’-ACAAGTCACCAATGGCTCCAC-3’ and
R: 5’-GCTTTGGTCAGAGTGTAGGTG-3’
fard-1 (native 3’ UTR, Figure 5D):
F: 5’-cgatagtgtgtctgttgattgtga-3’ and
R: 5’-agttattgttgatgagagagtgcg-3’
acl-7:
F: 5’-GTTTATGGCTGGCGTGTTG-3’ and
R: 5’-CGGAGAAGACAGCCCAGTAG-3’
ads-1:
F: 5’-GCGATTAACAAGGACGGACA-3’ and
R: 5’-CGATGCCCAAGTAGTTCTCG-3’.
Expression levels of tested genes were presented as normalized fold changes to the mRNA abundance of act-1 or pmp-3 for C. elegans by the ΔΔCt method.
fard-1 overexpression reporter fluorescence intensity analysis
Request a detailed protocolTo assess changes in levels of fluorescent FARD-1 protein in response to biguanide treatment, we used the strain MGH471 alxEx122[fard-1p::FARD-1::mRFP::HA unc-54 3'UTR myo-2p::GFP] (fard-1 oe1). In brief, egg prep synchronized L1 FARD-1::RFP transgenic worms were treated with vehicle (ddH2O) or 4.5 mM phenformin, paralyzed with 1 mg/mL of levamisole, and then imaged in 96-well format with a Leica DM6000 microscope outfitted with a mCherry filter set and MMAF software. These imaging experiments were carried out in biological triplicate with ~10 animals imaged per replicate. Images were qualitatively assessed to obtain conclusions and results were consistent between independent replicates.
Colocalization analysis of FARD-1::RFP and peroxisomally targeted GFP
Request a detailed protocolColocalization of GFP and RFP expression in vehicle- or phenformin-treated MGH607 was performed by Coloc2 (Fiji) on images taken on a Leica Thunder microscopy system. Since FARD-1::RFP in MGH607 is exogenously expressed, we performed 3 hr egg lays with ~30 gravid hermaphrodites expressing both GFP::PTS1 and FARD-1::RFP to synchronize L1s. The eggs were treated with vehicle (ddH2O) or 4.5 mM phenformin immediately after gravid hermaphrodites were removed, dried in a laminar flow hood, and allowed to incubate at 20°C until the worms were YA/early day 1 adults. To prepare for imaging, only worms expressing both GFP::PTS1 and FARD-1::RFP were picked onto slides containing dried 2% agar pads, immobilized in ~5 μL of 2.5 mM levamisole solution and covered with a coverslip. Images of the upper, mid, and lower intestine were taken for 30 individual worms per condition (15 worms per replicate for two biological replicates). We generated Pearson’s r values to assess the extent to which intestinal RFP and GFP overlap in each region of all samples. All Pearson’s r values were combined to generate four individual averages (one per condition) to perform an unpaired t-test.
Lipid droplet analysis
Request a detailed protocolThe strain MGH605 alxIs45[fard-1p::FARD-1::mRFP::HA::unc-54 3'UTR myo-2p::GFP] (fard-1 oe3) was used for this analysis. Preparation of worms for imaging was similar to our longevity assays but modified to incorporate staining of lipid droplets. Briefly, 6 cm RNAi plates were seeded with 250 μL bacteria expressing glo-4 RNAi [5×] and allowed to incubate for 24 hr at 20°C. One μM of green C1-BODIPY-C12 (D-3823, Invitrogen) diluted in 100 μL 1× phosphate buffer saline (PBS, pH 7.2) was then added to the RNAi bacteria lawn as in Soukas et al., 2009. The plates were immediately dried in a dark laminar flow hood, wrapped in aluminum foil to prevent photobleaching, and allowed to incubate at 20°C for 24–48 hr. These plates were treated with vehicle (ddH2O) or 4.5 mM phenformin as mentioned previously (while kept away from light). Egg prep synchronized worms were dropped onto plates and grown to day 1 adult stage. To prepare for confocal imaging, animals were rapidly picked onto slides containing dried 2% agar pads, immobilized in ~5 μL of 2.5 mM levamisole solution and covered with a coverslip. Lipid droplets were imaged by Zeiss LSM 800 Airyscan within 5 min of slide placement. Z-stacked images were obtained for the intestine near the tail end of 14 glo-4, vehicle-treated and 19 glo-4, phenformin-treated worms (two biological replicates per condition). Five planes were extracted (planes 1, 2, 4, 5, and 9) using ImageJ for all samples. For lipid droplet counting, quantification was performed using CellProfiler 4.2.1 (Stirling et al., 2021) where lipid droplets were identified as primary objects. The min/max range for typical object diameters was 3–67 pixels, and those objects outside of the diameter range were discarded. Planes were excluded entirely if the pipeline did not accurately capture individual lipid droplets for the vast majority of objects.
Oil-red-O staining
Request a detailed protocolOil-red-O (ORO) fat staining was conducted as outlined in Stuhr et al., 2022, In brief, worms were synchronized by bleach prep and allowed to hatch overnight for a synchronous L1 population. The next day, worms were dropped onto plates seeded with bacteria with or without phenformin and raised to 120 hr (day 3 adult stage). Worms were washed off plates with PBST, then rocked for 3 min in 40% isopropyl alcohol before being pelleted and treated with ORO in diH2O for 2 hr. Worms were pelleted after 2 hr and washed in PBST for 30 min before being imaged at ×5 magnification with the DIC filter on the Zeiss Axio Imager Erc color camera. A minimum of 200 worms in total (across three independent biological replicates) were assessed per condition for final quantification and evaluation.
Generation of metabolically inactive E. coli for lipidomic and lifespan studies
Request a detailed protocolPFA killing of OP50-1 E. coli was performed as previously described with slight modifications (Beydoun et al., 2021). 50 mL aliquots of OP50-1 liquid cultures grown overnight in LB media supplemented with 25 μg/mL streptomycin were dispensed into 250 mL Erlenmeyer flasks. Either 1× PBS (Life Technologies) for mock treatment or 4% PFA (Sigma-Aldrich) diluted in 1× PBS was added to each flask for a final concentration of 1% (vol/vol). Bacteria were then shaken in 37°C at 210 rpm for 2 hr to enable PFA inactivation. Cultures were then aseptically transferred into 50 mL conical centrifuge tubes, and then washed 6× with sterile PBS to remove residual PBS or PFA solution. After the final wash, bacterial pellets were then 10× concentrated in LB media supplemented with 25 μg/mL streptomycin, and 300 μL seeded onto freshly prepared NGM plates. Plates were allowed to dry for 2 days prior to use for GC/MS or lifespan analyses. A standard culture of OP50-1 grown overnight was similarly 10× concentrated and seeded as a ‘live OP50-1’ control to compare to mock-treated and PFA-treated bacterial conditions. Bacterial titer calculations were performed as previously described (Beydoun et al., 2021), removing an 10 μL aliquot of culture prior to plate seeding, diluting 10 times in 10-fold serial dilutions, and subsequently dispensing the 100 μL dilutions onto LB agar plates and aseptically spread across the surface evenly. Plates were incubated at 37°C overnight before counting colonies for colony forming units and titer calculations.
Asdf quantification
Request a detailed protocolORO-stained worms were placed on glass slides and a coverslip was placed over the sample. Worms were scored, as previously described (Stuhr et al., 2022). Worms were scored and images were taken with the Zeiss Axio Imager Erc color camera at ×5 magnification. Fat levels of worms were placed into three categories: non-Asdf, intermediate, and Asdf. Non-Asdf worms display no loss of fat and are stained dark red throughout most of the body (somatic and germ cells). Intermediate worms display significant fat loss from the somatic tissues, with portions of the intestine being clear, but ORO-stained fat deposits are still visible (somatic<germ cells). Asdf worms had most, if not all, observable somatic fat deposits depleted (germ cells only).
Fluorescence reporter imaging and quantification
Request a detailed protocolGFP imaging of CF3556 agIs6[dod-24p::GFP] and CL2166 dvIs19 [(pAF15)gst-4p::GFP::NLS] animals was performed using a fully automated, high-speed fluorescence Leica THUNDER 3D imaging station at ×5 magnification. Egg prep synchronized dod-24p::GFP or gst-4p::NLS::GFP animals were dropped onto NGM plates seeded with OP50-1, or RNAi plates seeded with L4440 (EV), skn-1, fard-1, acl-7, or ads-1 HT115 RNAi clones, treated with vehicle (water) or 4.5 mM phenformin, and grown to adult day 1 stage. Animals were rapidly picked onto slides containing dried 2% agar pads, immobilized in ~5 μL of 2.5 mM levamisole solution, and covered with a coverslip. Quantification was performed using ImageJ/Fiji (Schindelin et al., 2012), in which at least 10 animals per condition per replicate were randomly polygon traced, collected into an ROI manager, and measured for mean fluorescence intensity (MFI). MFI values per condition per replicate (n=3) were aggregated using Prism 9 (GraphPad) for visualization and subsequent statistical analysis.
Quantification and statistical analysis
Request a detailed protocolUnless otherwise indicated, the statistical differences between control and experimental groups were determined by two-tailed Student’s t-test (two groups), one-way ANOVA (more than two groups), or two-way ANOVA (two independent experimental variables), with corrected p-values <0.05 considered significant. Analyses conducting more than two comparisons were always corrected for multiple hypothesis testing. The log-rank test was used to determine significance in lifespan analyses using online OASIS2 (https://sbi.postech.ac.kr/oasis2/).
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting files; Source Data files have been provided for Figure 2 as Figure 2 - source data 1. These same data have been made publicly available and can be found at Dryad.
-
Dryad Digital RepositoryEther Lipid Biosynthesis Promotes Lifespan Extension and Enables Diverse Prolongevity Paradigms in Caenorhabditis elegans.https://doi.org/10.5061/dryad.wdbrv15tj
References
-
Glycosylated antitumor ether lipids: activity and mechanism of actionAnti-Cancer Agents in Medicinal Chemistry 14:592–606.https://doi.org/10.2174/1871520614666140309231144
-
Metformin as a tool to target agingCell Metabolism 23:1060–1065.https://doi.org/10.1016/j.cmet.2016.05.011
-
Controlling the false discovery rate: A practical and powerful approach to multiple testingJournal of the Royal Statistical Society 57:289–300.https://doi.org/10.1111/j.2517-6161.1995.tb02031.x
-
Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonistsThe Journal of Biological Chemistry 276:16015–16023.https://doi.org/10.1074/jbc.M100878200
-
Structural and functional roles of ether lipidsProtein & Cell 9:196–206.https://doi.org/10.1007/s13238-017-0423-5
-
Subcellular distribution and properties of acyl/alkyl dihydroxyacetone phosphate reductase in rodent liversArchives of Biochemistry and Biophysics 245:523–530.https://doi.org/10.1016/0003-9861(86)90245-6
-
Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementiaJournal of Lipid Research 48:2485–2498.https://doi.org/10.1194/jlr.P700023-JLR200
-
Topography of ether phospholipid biosynthesisBiochimica et Biophysica Acta 1006:1–8.https://doi.org/10.1016/0005-2760(89)90315-9
-
Genetic analysis of lysosomal trafficking in Caenorhabditis elegansMolecular Biology of the Cell 16:3273–3288.https://doi.org/10.1091/mbc.e05-01-0060
-
Posttranslational regulation of fatty acyl-CoA reductase 1, Far1, controls ether glycerophospholipid synthesisThe Journal of Biological Chemistry 285:8537–8542.https://doi.org/10.1074/jbc.M109.083311
-
VAPs and ACBD5 tether peroxisomes to the ER for peroxisome maintenance and lipid homeostasisThe Journal of Cell Biology 216:367–377.https://doi.org/10.1083/jcb.201608128
-
Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapyPharmacology & Therapeutics 165:114–131.https://doi.org/10.1016/j.pharmthera.2016.06.003
-
Disruption of blood-testis barrier dynamics in ether-lipid-deficient miceCell and Tissue Research 337:281–299.https://doi.org/10.1007/s00441-009-0809-7
-
Ethanolamine plasmalogens protect cholesterol-rich liposomal membranes from oxidation caused by free radicalsChemistry and Physics of Lipids 120:145–151.https://doi.org/10.1016/s0009-3084(02)00101-9
-
Molecular view of hexagonal phase formation in phospholipid membranesBiophysical Journal 87:3894–3900.https://doi.org/10.1529/biophysj.104.048710
-
Metformin improves healthspan and lifespan in miceNature Communications 4:2192.https://doi.org/10.1038/ncomms3192
-
Disappearance of plasmalogens from membranes of animal cells subjected to photosensitized oxidationThe Journal of Biological Chemistry 263:11597–11606.
-
MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insightsNucleic Acids Research 49:W388–W396.https://doi.org/10.1093/nar/gkab382
-
Computational analysis of lifespan experiment reproducibilityFrontiers in Genetics 8:92.https://doi.org/10.3389/fgene.2017.00092
-
Biochemical and high throughput microscopic assessment of fat mass in Caenorhabditis elegansJournal of Visualized Experiments 30:50180.https://doi.org/10.3791/50180
-
Quantitative profiling of lipid species in Caenorhabditis elegans with gas chromatography-mass spectrometryMethods in Molecular Biology 2144:111–123.https://doi.org/10.1007/978-1-0716-0592-9_10
-
Fiji: an open-source platform for biological-image analysisNature Methods 9:676–682.https://doi.org/10.1038/nmeth.2019
-
Relevance of the OCT1 transporter to the antineoplastic effect of biguanidesBiochemical and Biophysical Research Communications 414:694–699.https://doi.org/10.1016/j.bbrc.2011.09.134
-
A Caenorhabditis elegans model for ether lipid biosynthesis and functionJournal of Lipid Research 57:265–275.https://doi.org/10.1194/jlr.M064808
-
Exclusive localization in peroxisomes of dihydroxyacetone phosphate acyltransferase and alkyl-dihydroxyacetone phosphate synthase in rat liverJournal of Lipid Research 34:467–477.
-
Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissuesCancer Research 29:251–257.
-
A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytesBiopharmaceutics & Drug Disposition 30:476–484.https://doi.org/10.1002/bdd.684
-
Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens: production of the chemoattractant, 2-chlorohexadecanalThe Journal of Biological Chemistry 277:3842–3849.https://doi.org/10.1074/jbc.M109489200
-
FUdR causes a twofold increase in the lifespan of the mitochondrial mutant gas-1Mechanisms of Ageing and Development 132:519–521.https://doi.org/10.1016/j.mad.2011.08.006
-
Using Caenorhabditis elegans to uncover conserved functions of omega-3 and omega-6 fatty acidsJournal of Clinical Medicine 5:19.https://doi.org/10.3390/jcm5020019
-
Natural history of rhizomelic chondrodysplasia punctataAmerican Journal of Medical Genetics. Part A 118A:332–342.https://doi.org/10.1002/ajmg.a.20009
-
A possible role for plasmalogens in protecting animal cells against photosensitized killingThe Journal of Biological Chemistry 263:11590–11596.
Decision letter
-
Martin Sebastian DenzelReviewing Editor; Altos Labs, United Kingdom
-
Carlos IsalesSenior Editor; Augusta University, United States
Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.
Decision letter after peer review:
Thank you for submitting your article "Ether Lipid Biosynthesis Promotes Lifespan Extension and Enables Diverse Prolongevity Paradigms in Caenorhabditis elegans" for consideration by eLife. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Carlos Isales as the Senior Editor. The reviewers have opted to remain anonymous.
The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.
The reviewers and the reviewing editor find the paper important and compelling.
Essential revisions:
1) Experiments were done in the presence of FuDR. Given the potential side effect of this compound, it would be important to show that the key findings of ether lipid requirements for biguanide-mediated longevity are not affected by FuDR.
2) Further, it is important to assess the possibility that biguanides act via an effect on bacterial growth and thus indirect effects on worm metabolism.
3) Please explain in the text why different biguanide concentrations were used in different experiments.
4) Please address in the text the reviewer's question on the role of oxidative stress and the role of gst-4.
Reviewer #1 (Recommendations for the authors):
– Lipid metabolism and SKN-1 have been implicated in germline disruption longevity pathways (one example of several papers is PMID: 26196144). The longevity data here all appear to have been collected in the background of the fertility inhibitor FuDR. Although the use of FuDR is common in the field and justified, synergistic effects have been documented. The authors should address the question as to whether the key finding of ether lipid requirements for biguanide-mediated longevity is independent of the presence of FuDR.
– The authors state that biguanides do not stimulate expression of the skn-1 antioxidant defense effector gst-4 (Discussion, lines 580 – 582), and cite Cabreiro et al. 2013 and Onken and Driscoll, 2010 to support this – in fact, both these papers demonstrate the opposite, showing that biguanide treatment does result in increased gst-4 expression. This calls into question the author's suggestion that biguanides activate ether lipid biosynthesis and skn-1 signaling to trigger metabolic stress defenses rather than canonical oxidative stress pathways.
Minimally, this needs to be straightened out in terms of accurate citation and discussion.
Better, the argument might be addressed by looking at daf-16 and skn-1 downstream target expression with biguanide treatment or in fard-1(oe) mutants with and without ether lipid biosynthesis gene disruptions. Resistance to oxidative stress could be tested under similar conditions.
Less critical points that should be addressed:
The paper would benefit from just a little bit more description of the original genetic screen, although published in Wu 2016. The endpoint of the original screen was for growth/body size changes in high metformin; how did data translate to the longevity endpoint focus here?
Metformin is used in the clinic, phenformin is much less prescribed due to side effect complications. The authors do address reasons they chose to use phenformin in most studies, but the clinical differences between metformin and phenformin underscore how interesting it is to ask the question as to what the metabolic differences might be. A complete analysis is beyond this paper's scope, but simple testing for key findings, even simple lipid droplet impact and fat distribution using metformin (as in Figure 6) could define lipid distribution outcomes as a common feature; or possibly identify a difference.
One naturally wonders whether the over-expression of enzymes ads-1 and/or acl-7 would also be bioactive. I do not think these are essential studies to add, but if the authors have the information they should add it to the paper.
– Figure 1-B-D; E-G seems to share the same WT control for all presented data, authors should indicate that all tests run in the same control experiment if this is the case, and should confirm in methods that same-day WT controls are run in the same experimental test of each study.
– ads-1 and acl-7 mutants exhibit modest increases in longevity with metformin treatment; acl-7 + phen might be different at end stages. Authors do comment that the response is blunted but some note that not all impact of the drug is eliminated should be added.
– Although the text suggests fard-1, ads-1, acl-7 mutants are null or reduction of function, the assignment as to whether a particular locus is null, missense is not clear; please add a comment in methods.
In Figure 2 —figure supplement 2, the authors examine the localization of exogenously expressed FARD-1, and state that the localization of FARD-1 is not regulated by biguanide treatment (Results, lines 286 – 304). As FARD-1 is likely overexpressed in these experiments (as the authors themselves point out in later lifespan experiments using the fard-1 (oe1) construct, Figure 5A), it is possible that the localization pattern here is the result of an "activated" ether biosynthesis pathway state, and that further stimulation with biguanide treatment might not impact FARD-1 localization.
This caveat should be discussed; better for the authors to examine localization with FARD-1 expressed at endogenous levels with and without phenformin treatment.
The authors show that expression of ether lipid biosynthesis genes does not increase with biguanide treatment (Figure 2 —figure supplement 2; Results lines 305 – 313), and FARD-1::RFP levels decrease with phenformin treatment (Figure 2 —figure supplement 2M) and suggest that "post-translational negative feedback of ether lipids on the ether lipid biosynthetic pathway, as has been previously reported" (Results lines 311 – 313)--a citation for these results should be added.
These data argue against phenformin and fard-1 overexpression triggering downstream pathways in the same way. Although fard-1 oe increases lifespan in a manner that is not additive with phenformin treatment (Figure 5 A and B), fard-1 overexpression evidently does not trigger the same negative feedback mechanism, as overexpressed FARD-1 levels shown in Figure 2 —figure supplement 2 M appear to be high in vehicle controls, and are lowered with phenformin treatment. If both fard-1 overexpression and phenformin treatment signal similarly to trigger a post-translational negative feedback mechanism (which would presumably be important for lifespan extension), one would expect similar FARD-1 levels in fard-1 oe animals with and without phenformin treatment. It is possible that fard-1 overexpression simply overwhelms – or is insufficient to trigger – negative feedback mechanisms. Data showing overexpressed fard-1 mRNA and FARD-1 protein levels vs. endogenously expressed fard-1 and FARD-1, with and without biguanide treatment, would help clarify these seemingly paradoxical results.
Figure 3D (D-H) RNAi of three fatty acid desaturases (D-F) two fatty acid elongases (G and H) …blunt phenformin-mediated lifespan extension in wild type worms.
fat-1 RNAi extends lifespan, phen treatment brings this close to wt +phen, and there is no significant difference wt+phen vs. fat-1(RNAi) + phen; it might be technically reasonable to indicate the response is blunted (percent increase) but fat-1 does not appear to be all that impactful on longevity. These data do not impress regarding the importance of fat-1 in phenformin outcome; the discussion should be toned down or eliminated.
Page 439 Figure 6 legend Asdf in 3, independent ether..comma not needed.
In Figure 6, the authors show that phenformin inhibits fat accumulation in young adults in a manner that requires ether lipid biosynthesis gene expression. As a skn-1 gain-of-function mutant has a similar fat reduction phenotype that does not appear to be additive with phenformin treatment, and because lifespan extension with phenformin and lipid ether biosynthesis gene fard-1 overexpression requires skn-1, the authors suggest that biguanides increase ether lipid biosynthesis to trigger a low-fat, pro-longevity metabolic state through skn-1. To support this model, the authors could further explore the link between phenformin, ether lipid biosynthesis, and skn-1: is skn-1 expression required for the low-fat phenotype seen with phenformin treatment? Is the expression of ether lipid biosynthesis genes needed for the low-fat phenotype seen in skn-1 gf mutants? Do fard-1(oe) mutants display a similar low-fat phenotype? What is the state of ether lipid levels in skn-1 gf mutants (as compared to phenformin-treated animals in Figure 2E and fard-1 overexpressors in Figure 5G)?
Figure 5C-text suggests all three kds disrupt, not just ads-1, why not include data for other kds in the main figures?
Figure 7B model: Dietary restriction executed is really one type of a complex response, so it is a bit of an over-extension to extend to DR in general; this can be addressed by indicating eat-2 DR in the box. Comments on DR would be more compelling if a second model of DR-associated longevity were tested.
daf-16 is not needed for biguanide-associated longevity, but it is for fard-1(oe)-mediated longevity -either explain why the dashed lines are used for daf-16 in the legend or better adjust the figure to visually reflect this complexity.
Discussion line 499 start. Our results show that the biguanides metformin and phenformin promote lifespan extension by stimulating the biogenesis of ether lipids, prompting longevity promoting, metabolic stress defenses mediated by skn-1.
Data relate to phenformin action but not necessarily metformin. Please adjust.
Possible point for additional discussion. Metformin has been documented to intersect with the bacterial food source to influence longevity PMID: 23540700. This manuscript does not engage that story, but I would encourage authors to add a small statement regarding their take on the interface of the "microbiome" or bacterial influence on biguanide action and possibly ether lipid synthesis.
Finally, as the authors point out, identification of the specific lipids necessary for promoting healthy aging is not feasible here; with which I totally agree. The actual mechanism by which ether lipid synthesizing enzymes modulate extended survival for the isp-1, eat-2, and raga-1 backgrounds or +phenformin is not really defined by this work. Still, the highlight of a critical biosynthetic pathway in biguanide outcomes and the implication of SKN-1/NRF2 in the biology is of sufficient importance in the field to merit high-profile publication.
Reviewer #2 (Recommendations for the authors):
Key points to address:
– Address the impact of biguanides on bacterial growth (OP50, HT115) experimentally e.g. bacterial growth, the impact of heat-killed bacteria on key biguanide phenotypes, and their relationship to ether lipids. The impact of biguanide concentration should also be considered in this regard.
– Address whether different amounts of biguanide cause the same effect on ether lipids.
– Address the direct genetic connections between skn-1 and fard-1 (etc) e.g. by creating a fard-1; skn-1 gof double and examining fat +/- Phenformin. Alternatively, could this be examined using fat measurements from aak-2 and daf-16 +/- fard-1? It would be interesting to see if the mechanism is the same for all of these longevity processes and make the study of even broader relevance.
Other points:
– Are the error bars in Figure 1 S1A correct? The data is normalised to 1. I am also unclear of the logic here. Metformin makes the worms smaller, but fard-1 and acl-7 RNAi reverse this? Is this the same with the mutants?
– Line 283 – 'the' missing? + other punctuation errors scattered about.
– The theory that the web-like structures marked by FARD-1::RFP are the ER is intriguing. What magnification are these images taken at in Figure 2 S2? Readers would need that information to decipher this.
– The authors mention that a pathway of negative feedback on ether lipid biosynthesis has been reported please could you supply that reference as it is currently missing – line 313.
– How are the numbers of lipid droplets measured in Figure 6? Per area? Per whole worm?
– Please address the issue of skn-1 isoforms in the text. You have carried out skn-1 RNAi which in theory takes out all isoforms – have you confirmed this? My issue is whether the skn-1 gof mutants and the skn-1 RNAi are true opposites of each other. It is also important as you refer to it as skn-1/Nrf2 specifically. You could just remove the 2.
https://doi.org/10.7554/eLife.82210.sa1Author response
Essential revisions:
1) Experiments were done in the presence of FuDR. Given the potential side effect of this compound, it would be important to show that the key findings of ether lipid requirements for biguanide-mediated longevity are not affected by FuDR.
We thank the reviewers for this important comment, and now include as Figure 1 —figure supplement 2 lifespan analyses that rigorously indicate that loss of function mutations in the ether lipid biosynthetic machinery completely blunt both metformin and phenformin-mediated lifespan extension without the use of FUdR, with results comparable to that of FUdR -treated animals as previously shown. We include discussion of these results in the manuscript between lines 160 and 165.
2) Further, it is important to assess the possibility that biguanides act via an effect on bacterial growth and thus indirect effects on worm metabolism.
We thank the reviewers for highlighting this potential caveat. To address whether biguanide-mediated ether lipid induction relies on live bacteria, we leveraged a robust strategy to prevent both bacterial replication and metabolic activity of the OP50-1 E. coli food source via pre-treatment with 1% paraformaldehyde (PFA) for two hours prior to seeding on nematode growth medium (NGM) agar plates3. We confirm that 1% PFA treatment completely prevents bacterial replication, and that the pre-treatment process itself does not significantly abrogate bacterial titer production compared to standard OP50-1 plate seeding protocols (Figure 6 —figure supplement 2A). Using this approach, we verify through lipidomic FAME GC/MS analysis that biguanides drive somatic fatty acid depletion and increases 16:0 DMA species. Importantly, these effects do not rely on the OP50-1 food source being alive, suggesting that the effects of biguanides on increasing ether lipid biosynthesis and altering somatic lipid stores do not act directly through alterations in bacterial growth or metabolism (Figure 6 —figure supplement 2B-G). We additionally include lifespan analyses that reveal that biguanides still extend lifespan on metabolically killed OP50-1, and that ether lipid deficiency in ads-1 mutant animals completely abrogates both metformin and phenformin-mediated lifespan extension, even when grown on metabolically inactivated and dead bacteria (Figure 6 —figure supplement 3). Combined, these data rigorously advance the conclusion that the effects of biguanides on ether lipid biosynthesis and lifespan extension occurs directly through the nematode, and do not rely upon alterations in bacterial growth or metabolism to exert their pro-longevity effects. We include discussion of these new results in lines 509 to 547. Given that these results contrast with previously published work by others, and the importance to the field, we plan a whole separate manuscript about biguanide effects directly on nematode lifespan versus indirectly through the bacteria. As such, we do not dwell extensively on the subject herein.
3) Please explain in the text why different biguanide concentrations were used in different experiments.
We thank the reviewers for the opportunity to clarify the uses of different concentrations of biguanides in our assays. We wish to clarify that our current study is focused on the role of ether lipid machinery in modulation of lifespan and healthy aging – as such, we focused on genetic and biochemical experiments leveraging minimally lifespan extending doses of biguanides (4.5 mM phenformin and 50 mM metformin) to identify epistatic links and interactions, as utilized by several independent laboratories 4-9. The goal of the 160 mM dosage of metformin used in our prior genetic screens 10 and subsequently highlighted in Figure 1 —figure supplement 1A is to enhance the sensitivity and specificity of our discovery approach to identify effectors of the biological action of biguanides. The 160 mM dose we leveraged causes potent growth inhibition 10. Our prior published work indicates that using this dose to look for gene inactivations that block the growth inhibitory effects of the drug can also identify longevity effectors of metformin10. Thus, we used a similar strategy here to identify fard-1 and acl-7, which were initially identified as gene knockdowns that block the growth inhibitory effects of 160 mM metformin. Thereafter, lower doses of biguanides are used (4.5 mM phenformin and 50 mM metformin) to elucidate requirements of the ether lipid machinery in biguanide-prompted longevity. We succinctly modify in the text the reasoning for the different biguanide concentrations used in this work (lines 135 to 153).
4) Please address in the text the reviewer's question on the role of oxidative stress and the role of gst-4.
We thank the reviewers for allowing us to highlight this important clarification. We have performed reporter imaging experiments in the gst-4 transcriptional reporter strain gst-4p::GFP::NLS (included as Figure 6 —figure supplement 1A-B), suggesting that biguanides do not significantly activate gst-4 expression in either OP50 and HT115 dietary sources, and that phenformin treatment conversely significantly reduced gst-4 expression. We have repeated this experiment numerous times and at multiple timepoints in the lifespan. In fact, the analysis of gst-4 expression indicates that metformin and phenformin decrease gst-4 expression. These data substantiate our claim that the requirement of SKN-1 activity downstream of biguanides to mediate somatic lipid depletion and pro-longevity outcomes is not due to a gst-4 mediated antioxidant role. We additionally include reporter imaging data for expression of dod-24, a metabolic defense stress response factor known to be transcriptionally regulated by SKN-12, revealing that biguanides activate dod-24 expression via a mechanism dependent on both ether lipid machinery and SKN-1 activity (Figure 6F). Concordant with our prior work2, there are multiple “flavors” of skn-1 activation, and the metabolic “flavor” is oppositely regulated to oxidative defenses (thus leading to increased expression of dod-24 and decreased expression of gst-4). Given that these results conflict with the literature and the prevailing notions in the field. we describe these results in the revised text in the Results section in lines 497 to 508 and in the Discussion in lines 659 to 673.
Reviewer #1 (Recommendations for the authors):
1. Lipid metabolism and SKN-1 have been implicated in germline disruption longevity pathways (one example of several papers is PMID: 26196144). The longevity data here all appear to have been collected in the background of the fertility inhibitor FuDR. Although the use of FuDR is common in the field and justified, synergistic effects have been documented. The authors should address the question as to whether the key finding of ether lipid requirements for biguanide-mediated longevity is independent of the presence of FuDR.
We thank the reviewer for this suggestion. As noted in Author Response 1, we have performed lifespan experiments without the use of FUdR (included as Figure 1 —figure supplement 2) for wild type and ether lipid deficient mutants treated with either metformin or phenformin in biological triplicate. These new data reveal that the requirements for the ether lipid machinery in biguanide-mediated lifespan extension are independent of the effects of FUdR, with abrogation of lifespan extension seen in rates comparable to that when using FUdR (Figure 1B-G and Supplementary file 1). We address these important confirmatory results in the text under lines 160 to 165.
2. The authors state that biguanides do not stimulate expression of the skn-1 antioxidant defense effector gst-4 (Discussion, lines 580 – 582), and cite Cabreiro et al. 2013 and Onken and Driscoll, 2010 to support this – in fact, both these papers demonstrate the opposite, showing that biguanide treatment does result in increased gst-4 expression. This calls into question the author's suggestion that biguanides activate ether lipid biosynthesis and skn-1 signaling to trigger metabolic stress defenses rather than canonical oxidative stress pathways.
Minimally, this needs to be straightened out in terms of accurate citation and discussion.
Better, the argument might be addressed by looking at daf-16 and skn-1 downstream target expression with biguanide treatment or in fard-1(oe) mutants with and without ether lipid biosynthesis gene disruptions. Resistance to oxidative stress could be tested under similar conditions.
We thank the reviewer for highlighting this textual oversight, and for the opportunity to better expand upon our suggestion that biguanides rely upon SKN-1 induced metabolic stress defense to exert a pro-longevity outcome, independent of its known canonical oxidative stress response functions. We have corrected the discussion of the Onken and Driscoll, 2010 and Cabreiro et al., 2013 citations to highlight the previously published observations of a moderate ~1.5 to 2-fold increase in gst-4 expression with 50 mM metformin treatment4,5. We have attempted numerous times to reproduce this induction result with both 50 mM metformin and 4.5 mM phenformin administration, at multiple times across the lifespan. We include as Figure 6 —figure supplement 1A-B data that fails to replicate the subtle increase in gst-4 expression previously reported on either OP50-1 or HT115 food sources, and instead show that phenformin treatment significantly reduces gst-4 expression. We include as Figure 6F data that indicate that phenformin treatment activates expression of the metabolic stress defense factor dod-24, a known transcriptional target of the non-canonical SKN-1 innate immune effector regulon2. The induction of dod-24p::GFP expression is both skn-1 and ether lipid machinery dependent, analogous to the dependencies seen with adult somatic lipid depletion (Figure 6B-E). Thus, we argue that biguanides exert their pro-longevity outcomes via alterations in somatic lipid levels and metabolic stress defense response through an ether lipid and SKN-1 signaling axis independent of the transcription factor’s known role in inducing an oxidative stress response. We have included discussion of these new results in Results (lines 497-508) and (659-673) of the manuscript. The decrease in gst-4 expression seen with phenformin treatment is potentially of great interest, suggesting that phenformin treatment may increase the sensitivity of animals to oxidative stressors. We are focusing on follow ups of this result in manuscripts currently in preparation.
Less critical points that should be addressed:
3. The paper would benefit from just a little bit more description of the original genetic screen, although published in Wu 2016. The endpoint of the original screen was for growth/body size changes in high metformin; how did data translate to the longevity endpoint focus here?
We thank the reviewer for the opportunity to highlight the rationale for our original genetic screen in integration of growth and longevity outcomes. In our original study, we leveraged an RNAi library consisting of ~1000 genes annotated with a metabolic gene ontology to identify genetic elements required for metformin-mediated growth inhibition, to illuminate the physiologic mechanisms that regulate the drug’s known anti-neoplastic and anti-growth proliferative effects. We identified a pathway linking mitochondrial perturbation to improved nuclear pore complex (NPC) and nucleocytoplasmic trafficking function, resulting in reduced mTORC1 signaling and activation of biguanide response element CeACAD10 to induce growth inhibition10. We surprisingly found that improved NPC fidelity is not only required for the growth inhibitory properties of the drug, but were also necessary for the pro-longevity outcomes, suggesting a unified mechanism for both anti-cancer and lifespan extension10. Given our previous success in identifying genetic elements that bridge both the growth inhibitory and pro-longevity mechanisms of the drug, we were interested in identifying other hits from our genetic screen that may be required for both mechanisms, leading to our current study interrogating the role of ether lipid machinery in regulation of biguanide-mediated lifespan extension. We have amended the text in lines 135 to 153 to succinctly describe this transition.
4. Metformin is used in the clinic, phenformin is much less prescribed due to side effect complications. The authors do address reasons they chose to use phenformin in most studies, but the clinical differences between metformin and phenformin underscore how interesting it is to ask the question as to what the metabolic differences might be. A complete analysis is beyond this paper's scope, but simple testing for key findings, even simple lipid droplet impact and fat distribution using metformin (as in Figure 6) could define lipid distribution outcomes as a common feature; or possibly identify a difference.
We agree with the reviewer that the potential link between clinical differences and metabolic outcomes of metformin and phenformin administration are alluring to investigate and of upmost importance to clarify. We are currently preparing a manuscript in which we thoroughly dissect the differential metabolic responses to metformin and phenformin in nematodes, and highlight their relationship to stress response, pro-longevity, and growth inhibitory outcomes. We believe that the lipid distribution experiments as suggested by the reviewer will be of critical importance in our next manuscript but is beyond the scope of this manuscript, specifically highlighting the unified importance of ether lipid machinery in both metformin and phenformin-mediated lifespan extension.
5. One naturally wonders whether the over-expression of enzymes ads-1 and/or acl-7 would also be bioactive. I do not think these are essential studies to add, but if the authors have the information they should add it to the paper.
We thank the reviewer for this insightful suggestion. We are currently working on developing these genetic reagents for future studies that will finely delineate the specific nodes during ether lipid biosynthesis that may confer pro-longevity and healthspan benefits in the nematode.
6. Figure 1-B-D; E-G seems to share the same WT control for all presented data, authors should indicate that all tests run in the same control experiment if this is the case, and should confirm in methods that same-day WT controls are run in the same experimental test of each study.
We apologize for the oversight in clearly highlighting that the lifespan analyses shown in Figure 1B-D;E-G are representative of results from 1 replicate run in the same batch with same-day wildtype controls. We amend in the figure legends for Figure 1 and Materials and methods sections that this is the case (lines 179 to 180) and note that additional replicates with independent wild type controls and all appropriate statistics for comparisons are included as Supplementary file 1.
7. ads-1 and acl-7 mutants exhibit modest increases in longevity with metformin treatment; acl-7 + phen might be different at end stages. Authors do comment that the response is blunted but some note that not all impact of the drug is eliminated should be added.
We thank the reviewer for their careful interpretation of our lifespan analyses. We have amended the text in lines 153 to 155 to note that ads-1 and acl-7 mutants may display a modest increase in lifespan with metformin administration, but with a percentage median lifespan increase significantly reduced in comparison to wildtype controls (Supplementary file 1). We also note that although these mutations result in a loss of function of the protein, they are missense mutations, and thus a small amount of residual ether lipid biosynthetic capacity cannot be completely ruled out (see the following comment in the response to point 8 below).
8. Although the text suggests fard-1, ads-1, acl-7 mutants are null or reduction of function, the assignment as to whether a particular locus is null, missense is not clear; please add a comment in methods.
We have included in the Strain subsection in the Materials and methods (lines 721 to 723) a description of the genetic lesions in each of the mutants. fard-1(wa28) (G261D), acl-7 (wa20) (R234C), and ads-1(wa3) (G454D) are all missense mutations that result in a loss of nearly all detectable DMA synthesis11. Although these mutations generate a loss-of-function effect, a small amount of residual ether lipid biosynthetic capacity cannot be completely ruled out in these animals.
9. In Figure 2 —figure supplement 2, the authors examine the localization of exogenously expressed FARD-1, and state that the localization of FARD-1 is not regulated by biguanide treatment (Results, lines 286 – 304). As FARD-1 is likely overexpressed in these experiments (as the authors themselves point out in later lifespan experiments using the fard-1 (oe1) construct, Figure 5A), it is possible that the localization pattern here is the result of an "activated" ether biosynthesis pathway state, and that further stimulation with biguanide treatment might not impact FARD-1 localization.
10. This caveat should be discussed; better for the authors to examine localization with FARD-1 expressed at endogenous levels with and without phenformin treatment.
We appreciate the reviewer highlighting the important caveat of relying on exogenous overexpression systems for colocalization and co-interaction studies. We include this as a limitation of our current study in lines 650 to 658, and efforts are currently underway to endogenously tag FARD-1 but are not available at the time of this revision.
11. The authors show that expression of ether lipid biosynthesis genes does not increase with biguanide treatment (Figure 2 —figure supplement 2; Results lines 305 – 313), and FARD-1::RFP levels decrease with phenformin treatment (Figure 2 —figure supplement 2M) and suggest that "post-translational negative feedback of ether lipids on the ether lipid biosynthetic pathway, as has been previously reported" (Results lines 311 – 313)--a citation for these results should be added.
We apologize for this oversight and have included the citation for Honsho, et al. 2010 in lines 312 and 6481.
12. These data argue against phenformin and fard-1 overexpression triggering downstream pathways in the same way. Although fard-1 oe increases lifespan in a manner that is not additive with phenformin treatment (Figure 5 A and B), fard-1 overexpression evidently does not trigger the same negative feedback mechanism, as overexpressed FARD-1 levels shown in Figure 2 —figure supplement 2 M appear to be high in vehicle controls, and are lowered with phenformin treatment. If both fard-1 overexpression and phenformin treatment signal similarly to trigger a post-translational negative feedback mechanism (which would presumably be important for lifespan extension), one would expect similar FARD-1 levels in fard-1 oe animals with and without phenformin treatment. It is possible that fard-1 overexpression simply overwhelms – or is insufficient to trigger – negative feedback mechanisms. Data showing overexpressed fard-1 mRNA and FARD-1 protein levels vs. endogenously expressed fard-1 and FARD-1, with and without biguanide treatment, would help clarify these seemingly paradoxical results.
We thank the reviewer for this important suggestion, and we have performed the experiment as suggested. We include in Figure 5G-H qRT-PCR analysis of wild type and fard-1(oe3) animals treated with phenformin, evaluating the RNA expression levels of endogenous fard-1 (using qRT-PCR primers probing for the native 3’ UTR of fard-1, Figure 5D). These results indicate that FARD-1 overexpression indeed reduces native fard-1 expression by ~40%, and that biguanide treatment does not additively reduce fard-1 expression even further. Interestingly, biguanide treatment appears to reduce the expression of exogenously overexpressed fard-1 by about ~60%, consistent with the reduction in RFP-tagged protein levels shown in Figure 2 —figure supplement 2M. We speculate that the discrepancy in feedback mechanisms between the endogenous and exogenous fard-1 transcripts is likely due to the design of the overexpressor, as the fard-1(oe) strains in this manuscript all utilize a synthetic unc-54 3’ UTR to enhance permissive expression in all C. elegans somatic cells, and likely maintain expression as a multicopy integrant in the genome, thus overwhelming negative feedback mechanisms. Indeed, several studies have suggested that the 3’ UTR structure of several mRNAs mediate negative feedback loops to finely tune protein expression patterns12,13. Combined, these results suggest that FARD-1 overexpression and biguanide treatment regulate endogenous fard-1 levels through similar mechanisms, but the differential UTR utilization and potential for multicopy integration may explain their distinct lifespan promoting dependencies. We discuss the significance of these results in lines 650 through 655.
13. Figure 3D (D-H) RNAi of three fatty acid desaturases (D-F) two fatty acid elongases (G and H) …blunt phenformin-mediated lifespan extension in wild type worms.
fat-1 RNAi extends lifespan, phen treatment brings this close to wt +phen, and there is no significant difference wt+phen vs. fat-1(RNAi) + phen; it might be technically reasonable to indicate the response is blunted (percent increase) but fat-1 does not appear to be all that impactful on longevity. These data do not impress regarding the importance of fat-1 in phenformin outcome; the discussion should be toned down or eliminated.
We thank the reviewer for their careful interpretation of the lifespan results for fat-1 RNAi. We agree that there does not appear to be a meaningful or interpretable interaction between fat-1 and biguanide action in longevity, and so we have removed the fat-1 data and reference to it from this version of the text.
14. Page 439 Figure 6 legend Asdf in 3, independent ether..comma not needed
We have deleted this comma and thoroughly checked the remainder of the manuscript for punctuation and grammatical errors.
15. In Figure 6, the authors show that phenformin inhibits fat accumulation in young adults in a manner that requires ether lipid biosynthesis gene expression. As a skn-1 gain-of-function mutant has a similar fat reduction phenotype that does not appear to be additive with phenformin treatment, and because lifespan extension with phenformin and lipid ether biosynthesis gene fard-1 overexpression requires skn-1, the authors suggest that biguanides increase ether lipid biosynthesis to trigger a low-fat, pro-longevity metabolic state through skn-1. To support this model, the authors could further explore the link between phenformin, ether lipid biosynthesis, and skn-1: is skn-1 expression required for the low-fat phenotype seen with phenformin treatment? Is the expression of ether lipid biosynthesis genes needed for the low-fat phenotype seen in skn-1 gf mutants? Do fard-1(oe) mutants display a similar low-fat phenotype? What is the state of ether lipid levels in skn-1 gf mutants (as compared to phenformin-treated animals in Figure 2E and fard-1 overexpressors in Figure 5G)?
We thank the reviewer for these highly insightful suggestions to better delineate the link between SKN-1 and ether lipid synthesis with biguanide-mediated low-fat metabolic states. We now include as Figure 6D-E Asdf analysis of wildtype and skn-1(zu135) complete loss-of-function animals treated with phenformin, showing that SKN-1 is absolutely required for biguanide-mediated somatic depletion of fat. We amended Figure 6B-C to include Asdf analysis of FARD-1 overexpressing animals, indicating that fard-1 (oe1) animals indeed constitutively activate a low somatic fat state. To elucidate the state of ether lipid levels in skn-1gf mutants, we performed FAME GC/MS analysis of lipids extracted from skn-1gf(lax188) animals relative to wildtype (N2) at adult day 2 of lifespan. As shown in Author response image 1, skn-1gf animals differentially alter ether lipid synthesis in a manner distinct from FARD-1 overexpression indicated in Figure 5I, increasing 18:0 DMA levels while nominally altering 16:0 DMA and 18:1 DMA levels. Combined, these three results corroborate the model that biguanides induce a somatic fat depleted state through a mechanism dependent on SKN-1 activity downstream of activation of the ether lipid biosynthetic machinery.

Gain of function mutation in SKN-1 results in global depletion of free fatty acid levels and elevates ether lipid precursor alcohols.
(A) Quantification of total area under the curve (AUC) measurements for all identified free fatty acids (FFA) in wildtype (N2) and skn-1gf(lax188) animals at Adult Day 2 using fatty acid methyl ester extraction followed by gas chromatography – mass spectrometry (FAME GC/MS). (B) Quantification of alkenyl dimethylacetal fatty alcohols (DMA) in N2 and skn-1gf(lax188) animals at Adult Day 2 using FAME GC/MS. Data are total sum normalized to percentage of total FFA pool. For A-B, data represent the mean +/- SEM of n = 4 independent biological replicates. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by Student’s t-test (A) or multiple t-tests with multiple hypothesis correction by two-stage step-up method of Benjamini, Krieger, and Yekutieli (B).
16. Figure 5C-text suggests all three kds disrupt, not just ads-1, why not include data for other kds in the main figures?
We appreciate the reviewers’ suggestion, and, in addition to ads-1 (Figure 5C) also now include data indicating that RNAi knockdown of fard-1 and acl-7 similarly suppresses FARD-1 overexpression -mediated lifespan extension as Figure 5 —figure supplement 1A-B.
17. Figure 7B model: Dietary restriction executed is really one type of a complex response, so it is a bit of an over-extension to extend to DR in general; this can be addressed by indicating eat-2 DR in the box. Comments on DR would be more compelling if a second model of DR-associated longevity were tested.
We appreciate the reviewers’ comments and have amended the model in Figure 7B to now state ‘EAT-2 DR’.
18. daf-16 is not needed for biguanide-associated longevity, but it is for fard-1(oe)-mediated longevity -either explain why the dashed lines are used for daf-16 in the legend or better adjust the figure to visually reflect this complexity.
We now explicitly detail the reasoning for the dashed lines in DAF-16 in the legend for Figure 7B (lines 713 to 716). We wished to indicate the point that the reviewer suggests – that DAF-16 is required for FARD-1 overexpression but not biguanide-mediated lifespan extension.
19. Discussion line 499 start. Our results show that the biguanides metformin and phenformin promote lifespan extension by stimulating the biogenesis of ether lipids, prompting longevity promoting, metabolic stress defenses mediated by skn-1.
Data relate to phenformin action but not necessarily metformin. Please adjust.
We adjust the text as suggested by the reviewer to indicate phenformin only in line 577.
20. Possible point for additional discussion. Metformin has been documented to intersect with the bacterial food source to influence longevity PMID: 23540700. This manuscript does not engage that story, but I would encourage authors to add a small statement regarding their take on the interface of the "microbiome" or bacterial influence on biguanide action and possibly ether lipid synthesis.
We thank the reviewer for this critical suggestion, which was additionally suggested by Reviewer #2 and the Reviewing Editor for experimental evaluation. As indicated in Author Response 3, we have performed FAME GC/MS of Adult Day 1 nematodes treated with or without phenformin and grown on live or metabolically dead OP50-1 E. coli food sources3. These analyses rigorously show that biguanides increase nematode ether lipid levels independent of any indirect effects on bacterial growth, proliferation, or metabolism (Figure 2 —figure supplement 3). Compellingly, metabolically inactivating the bacterial food source does not impair the ability of the ether lipid machinery to abrogate biguanide-mediated lifespan extension (Figure 2 —figure supplement 4). Additionally, our previously published study interrogating the role of CeACAD10 in regulation of metformin action in growth and cancer highlights that UV-mediated inactivation of OP50-1 growth does not affect metformin-mediated growth inhibition, and that direct injection of metformin into the animal is sufficient to drive CeACAD10 biguanide response activation14. Combined, these data rigorously exclude the possibility that biguanides alter ether lipid levels or the activity of the machinery via indirect effects through bacterial metabolism. We include a new section in Results to highlight this important statement (lines 509 to 547) and include a brief description of these results in the Discussion (lines 577 to 580).
21. Finally, as the authors point out, identification of the specific lipids necessary for promoting healthy aging is not feasible here; with which I totally agree. The actual mechanism by which ether lipid synthesizing enzymes modulate extended survival for the isp-1, eat-2, and raga-1 backgrounds or +phenformin is not really defined by this work. Still, the highlight of a critical biosynthetic pathway in biguanide outcomes and the implication of SKN-1/NRF2 in the biology is of sufficient importance in the field to merit high-profile publication.
We again thank the reviewer for their support of our work and for their excellent feedback, which greatly strengthened the mechanistic underpinnings of our work.
Reviewer #2 (Recommendations for the authors):
Key points to address:
1. Address the impact of biguanides on bacterial growth (OP50, HT115) experimentally e.g. bacterial growth, the impact of heat-killed bacteria on key biguanide phenotypes, and their relationship to ether lipids. The impact of biguanide concentration should also be considered in this regard.
We thank the reviewer for this important suggestion, and we have performed the experiment as suggested. As indicated in Author Responses 3 and 22, we have performed FAME GC/MS of adult day 1 nematodes treated with or without phenformin and grown on live or metabolically dead OP50-1 E. coli food sources using a rigorously established 1% PFA treatment protocol 3. This PFA treatment protocol, as opposed to heat or UV killing protocols, both completely kill and metabolically inactivate the food source (Figure 6 —figure supplement 2A), making this a more reliable, uniformly consistent strategy to eliminate bacterial growth and metabolism as confounding variables in lipidomic and lifespan analyses 3. These analyses rigorously show that biguanides increase relative nematode ether lipid levels independent of any indirect effects on bacterial growth, proliferation, or metabolism (Figure 6 —figure supplement 2D-G). Compellingly, metabolic inactivation of the bacterial food source neither impairs the lifespan extending effects of biguanides nor impairs the ability of the ether lipid machinery to abrogate biguanide-mediated lifespan extension (Figure 6 —figure supplement 3A-F). Combined, these data rigorously exclude the possibility that biguanides alter ether lipid levels or the activity of the machinery via indirect effects through bacterial growth or metabolism. We performed experiments utilizing a final dosage of 4.5 mM phenformin and 50 mM metformin, both of which are minimally required to robustly and reproducibly extend C. elegans lifespan, as corroborated and utilized by several independent laboratories7-10. Thus, these data strengthen the conclusion that phenformin and metformin prompt ether lipid-dependent increases in lifespan via direct effects on the worm, i.e. independently of biguanide effects on bacteria. Given that these results contrast with previously published work by others, and the importance to the field, we plan a whole separate manuscript about biguanide effects directly on nematode lifespan versus indirectly through the bacteria. As such we do not dwell extensively on the subject herein.
2. Address whether different amounts of biguanide cause the same effect on ether lipids.
We thank the reviewer for this suggestion. We again wish to clarify to the reviewer that the intention of this study is to illuminate the requirements for ether lipid biosynthesis on the pro-longevity mechanism of biguanides. As such, we utilized doses of metformin and phenformin that minimally robustly extend C. elegans lifespan (4.5 mM phenformin and 50 mM metformin) without resulting in negative pleiotropies, as utilized by multiple independent laboratories to identify genetic regulators of the drug7-10. The supraphysiological 160 mM dosage of metformin used in our prior genetic screens was only initially utilized to identify biguanide response elements. Given that the prior literature shows that higher doses of biguanides do not positively influence C. elegans lifespan5,7, even if additive effects on ether lipids were evident, we argue that they are not relevant to the major thrust of this manuscript on longevity-promoting effects of biguanides and ether lipids.
3. Address the direct genetic connections between skn-1 and fard-1 (etc) e.g. by creating a fard-1; skn-1 gof double and examining fat +/- Phenformin. Alternatively, could this be examined using fat measurements from aak-2 and daf-16 +/- fard-1? It would be interesting to see if the mechanism is the same for all of these longevity processes and make the study of even broader relevance.
We thank the reviewer for this suggestion. To clarify, we believe that SKN-1 is the transcription factor operating downstream of the ether lipid machinery to induce somatic lipid depletion, metabolic stress defenses, and pro-longevity outcomes. We have multiple lines of evidence to support this conclusion: (1) A skn-1 RNAi targeting all isoforms of SKN-1 completely abrogates the pro-longevity effects of fard-1 (oe1) animals (Figure 5D), (2) a total SKN-1 loss-of-function mutant completely prevents both biguanide-mediated lifespan extension4 and somatic lipid depletion phenotypes (Figure 6D-E), and (3) skn-1gf animals displaying depleted somatic lipid content elevate 18:0 DMA levels (Response Figure 1), in contrast to changes in 16:0 DMA and 18:1 DMA in fard-1 (oe3) animals, suggesting that skn-1gf alone does not mirror FARD-1 overexpression mediated changes in ether lipid levels. As such, we do not believe that a fard-1lf,skn-1gf animal will suppress the skn-1gf Asdf phenotype. We agree that it would be interesting to see if multiple pro-longevity paradigms known to activate the major pro-longevity signaling and transcription factors AAK-2 and DAF-16 similarly control somatic lipid depletion, but we believe that this is outside of the scope of this initial manuscript delineating the role of SKN-1 and ether lipid machinery in regulation of biguanide-mediated lipid depletion and lifespan extension.
Other points:
4. Are the error bars in Figure 1 S1A correct? The data is normalised to 1. I am also unclear of the logic here. Metformin makes the worms smaller, but fard-1 and aCl-7 RNAi reverse this? Is this the same with the mutants?
We thank the reviewer for the opportunity to clarify the results and significance of our growth inhibition assay in Figure 1 —figure supplement 1A. We have clarified in the figure legend that the bars in Figure 1 —figure supplement 1A are in fact SEM. The reviewer is correct in their interpretation of our data, that RNAi inactivation of fard-1 and acl-7 significantly blunt the growth inhibitory properties of the drug. These results corroborate the findings from our initial ~1000 metabolism gene RNAi screen for genetic elements that control metformin-induced growth inhibition, implicating the ether lipid machinery as critical for the growth inhibitory properties of the drug. Since this experiment was only used to identify potential response elements, we did not test the genetic mutants in the growth inhibition assay. Instead, we shifted our experimentation to address whether the ether lipid machinery is required for biguanide-mediated lifespan extension, which is the major thrust of the manuscript.
5. Line 283 – 'the' missing? + other punctuation errors scattered about.
We thank the reviewer for catching this typo. All authors have carefully examined the rest of this revised manuscript for punctuation and grammatical mistakes.
6. The theory that the web-like structures marked by FARD-1::RFP are the ER is intriguing. What magnification are these images taken at in Figure 2 S2? Readers would need that information to decipher this.
The images in Figure 2 —figure supplement 2 were taken using a Zeiss Plan-Apochromat 63x/1.4 Oil DIC M27 objective with a 2.0 scan zoom for each field. We have included the details of this magnification in the figure legend for Figure 2 —figure supplement 2F (lines 1463 to 1465)
7. The authors mention that a pathway of negative feedback on ether lipid biosynthesis has been reported please could you supply that reference as it is currently missing – line 313.
We apologize to the reviewer for our oversight on including this reference. We have included the appropriate reference1 as requested in lines 312 and 648.
8. How are the numbers of lipid droplets measured in Figure 6? Per area? Per whole worm?
We thank the reviewer for this important clarification. We include details regarding the measurements of lipid droplets in the Materials and methods section under ‘Lipid droplet analysis’ (lines 964 to 986). Z-stacked images were obtained for the intestine near the tail end of 14 glo-4 RNAi, vehicle treated and 19 glo-4 RNAi, phenformin treated worms (2 biological replicates per condition). 5 planes were extracted (planes 1,2,4,5, and 9) using ImageJ for all samples. For lipid droplet counting, quantification was performed using CellProfiler 4.2.115 where lipid droplets were identified as primary objects. The min/max range for typical object diameters was 3-67 pixels, and those objects outside of the diameter range were discarded. Planes were excluded entirely if the pipeline did not accurately capture individual lipid droplets for most objects.
9. Please address the issue of skn-1 isoforms in the text. You have carried out skn-1 RNAi which in theory takes out all isoforms – have you confirmed this? My issue is whether the skn-1 gof mutants and the skn-1 RNAi are true opposites of each other. It is also important as you refer to it as skn-1/Nrf2 specifically. You could just remove the 2.
As suggested by the reviewer, we have changed all designations of skn-1/Nrf2 to skn-1/Nrf throughout this manuscript. Although the sequence verified Ahringer Library skn-1 RNAi clone utilized for RNAi knockdown experiments has been previously shown to target and abrogate expression of all 4 SKN-1 transcript isoforms2,16-18, we agree that we cannot rigorously conclude which SKN-1 isoform(s) is/are required for biguanide- or FARD-1 overexpression-mediated lifespan extension, and further, which orthologous Nrf function is represented.
References:
1. Honsho, M., Asaoku, S., and Fujiki, Y. (2010). Posttranslational regulation of fatty acyl-CoA reductase 1, Far1, controls ether glycerophospholipid synthesis. J Biol Chem 285, 8537-8542. 10.1074/jbc.M109.083311.
2. Nhan, J.D., Turner, C.D., Anderson, S.M., Yen, C.A., Dalton, H.M., Cheesman, H.K., Ruter, D.L., Uma Naresh, N., Haynes, C.M., Soukas, A.A., et al. (2019). Redirection of SKN-1 abates the negative metabolic outcomes of a perceived pathogen infection. Proc Natl Acad Sci U S A 116, 22322-22330. 10.1073/pnas.1909666116.
3. Beydoun, S., Choi, H.S., Dela-Cruz, G., Kruempel, J., Huang, S., Bazopoulou, D., Miller, H.A., Schaller, M.L., Evans, C.R., and Leiser, S.F. (2021). An alternative food source for metabolism and longevity studies in Caenorhabditis elegans. Commun Biol 4, 258. 10.1038/s42003-021-01764-4.
4. Onken, B., and Driscoll, M. (2010). Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS ONE 5, e8758. 10.1371/journal.pone.0008758.
5. Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H.M., Noori, T., Weinkove, D., Schuster, E., Greene, N.D.E., and Gems, D. (2013). Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153, 228-239. 10.1016/j.cell.2013.02.035.
6. Pryor, R., Norvaisas, P., Marinos, G., Best, L., Thingholm, L.B., Quintaneiro, L.M., De Haes, W., Esser, D., Waschina, S., Lujan, C., et al. (2019). Host-Microbe-Drug-Nutrient Screen Identifies Bacterial Effectors of Metformin Therapy. Cell 178, 1299-1312 e1229. 10.1016/j.cell.2019.08.003.
7. Espada, L., Dakhovnik, A., Chaudhari, P., Martirosyan, A., Miek, L., Poliezhaieva, T., Schaub, Y., Nair, A., Doring, N., Rahnis, N., et al. (2020). Loss of metabolic plasticity underlies metformin toxicity in aged Caenorhabditis elegans. Nat Metab 2, 1316-1331. 10.1038/s42255-020-00307-1.
8. Chen, J., Ou, Y., Li, Y., Hu, S., Shao, L.W., and Liu, Y. (2017). Metformin extends C. elegans lifespan through lysosomal pathway. eLife 6. 10.7554/eLife.31268.
9. Ma, T., Tian, X., Zhang, B., Li, M., Wang, Y., Yang, C., Wu, J., Wei, X., Qu, Q., Yu, Y., et al. (2022). Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature 603, 159-165. 10.1038/s41586-022-04431-8.
10. Wu, L., Zhou, B., Oshiro-Rapley, N., Li, M., Paulo, J.A., Webster, C.M., Mou, F., Kacergis, M.C., Talkowski, M.E., Carr, C.E., et al. (2016). An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer. Cell 167, 1705-1718 e1713. 10.1016/j.cell.2016.11.055.
11. Shi, X., Tarazona, P., Brock, T.J., Browse, J., Feussner, I., and Watts, J.L. (2016). A Caenorhabditis elegans model for ether lipid biosynthesis and function. J Lipid Res 57, 265-275. 10.1194/jlr.M064808.
12. Devany, E., Zhang, X., Park, J.Y., Tian, B., and Kleiman, F.E. (2013). Positive and negative feedback loops in the p53 and mRNA 3' processing pathways. Proc Natl Acad Sci U S A 110, 3351-3356. 10.1073/pnas.1212533110.
13. Perez-Diaz, L., Pastro, L., Smircich, P., Dallagiovanna, B., and Garat, B. (2013). Evidence for a negative feedback control mediated by the 3' untranslated region assuring the low expression level of the RNA binding protein TcRBP19 in T. cruzi epimastigotes. Biochem Biophys Res Commun 436, 295-299. 10.1016/j.bbrc.2013.05.096.
14. Wu, L., Zhou, B., Oshiro-Rapley, N., Li, M., Paulo, J.A., Webster, C.M., Mou, F., Kacergis, M.C., Talkowski, M.E., Carr, C.E., et al. (2016). An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer. Cell 167, 1705-1718.e1713. 10.1016/j.cell.2016.11.055.
15. Stirling, D.R., Swain-Bowden, M.J., Lucas, A.M., Carpenter, A.E., Cimini, B.A., and Goodman, A. (2021). CellProfiler 4: improvements in speed, utility and usability. BMC Bioinformatics 22, 433. 10.1186/s12859-021-04344-9.
16. Deng, J., Dai, Y., Tang, H., and Pang, S. (2020). SKN-1 Is a Negative Regulator of DAF-16 and Somatic Stress Resistance in Caenorhabditis elegans. G3 (Bethesda) 10, 1707-1712. 10.1534/g3.120.401203.
17. Frankino, P.A., Siddiqi, T.F., Bolas, T., Bar-Ziv, R., Gildea, H.K., Zhang, H., Higuchi-Sanabria, R., and Dillin, A. (2022). SKN-1 regulates stress resistance downstream of amino catabolism pathways. iScience 25, 104571. 10.1016/j.isci.2022.104571.
18. Steinbaugh, M.J., Narasimhan, S.D., Robida-Stubbs, S., Moronetti Mazzeo, L.E., Dreyfuss, J.M., Hourihan, J.M., Raghavan, P., Operana, T.N., Esmaillie, R., and Blackwell, T.K. (2015). Lipid-mediated regulation of SKN-1/Nrf in response to germ cell absence. eLife 4. 10.7554/eLife.07836.
https://doi.org/10.7554/eLife.82210.sa2Article and author information
Author details
Funding
National Institutes of Health (R01AG058259)
- Alexander A Soukas
National Institutes of Health (R01AG69677)
- Alexander A Soukas
National Institutes of Health (R01AG058610)
- Sean P Curran
National Science Foundation (Graduate Research Fellowship Program Award 1000253984)
- Lucydalila Cedillo
National Institutes of Health (R01AI130289)
- Read Pukkila-Worley
National Institutes of Health (K12GM106996)
- Lucydalila Cedillo
University of Southern California and Buck Institute Nathan Shock Center (P30AG068345)
- Sean P Curran
Nutrition Obesity Research Center at Harvard (P30DK040561)
- Alexander A Soukas
NIH/NIDDK-funded Boston-Area DERC (P30DK057521)
- Alexander A Soukas
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
We thank Talia Hart, Dr. Gary Ruvkun, Dr. Eric Greer, and Dr. Keith Blackwell for discussions and constructive criticisms. This work was funded by NIH/NIA Grants R01AG058259 and R01AG69677 (to AAS) and R01AG058610 (to SPC), by the Weissman Family MGH Research Scholar Award (to AAS), by an NSF GRFP Award 1000253984 (to LC), and by NIH/NIAID R01AI130289 (to RPW), and by IRACDA NIH Grant K12GM106996 (to LC). Thanks to the University of Southern California and Buck Institute Nathan Shock Center (P30AG068345) for providing core services and support. Thanks to the NIH/NIDDK-funded NORC of Harvard (P30DK040561) and the NIH/NIDDK-funded Boston-Area DERC (P30DK057521) for core services. Some strains were provided by the CGC, funded by the NIH Office of Research Infrastructure Programs (P40OD010440), and the C. elegans Knockout Consortium. Figures 1A, 3C and 7 were created with BioRender.com.
Senior Editor
- Carlos Isales, Augusta University, United States
Reviewing Editor
- Martin Sebastian Denzel, Altos Labs, United Kingdom
Version history
- Preprint posted: September 3, 2021 (view preprint)
- Received: July 27, 2022
- Accepted: July 13, 2023
- Version of Record published: August 22, 2023 (version 1)
Copyright
© 2023, Cedillo, Ahsan et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 463
- Page views
-
- 92
- Downloads
-
- 0
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Epidemiology and Global Health
- Genetics and Genomics
Accurate inference of who infected whom in an infectious disease outbreak is critical for the delivery of effective infection prevention and control. The increased resolution of pathogen whole-genome sequencing has significantly improved our ability to infer transmission events. Despite this, transmission inference often remains limited by the lack of genomic variation between the source case and infected contacts. Although within-host genetic diversity is common among a wide variety of pathogens, conventional whole-genome sequencing phylogenetic approaches exclusively use consensus sequences, which consider only the most prevalent nucleotide at each position and therefore fail to capture low frequency variation within samples. We hypothesized that including within-sample variation in a phylogenetic model would help to identify who infected whom in instances in which this was previously impossible. Using whole-genome sequences from SARS-CoV-2 multi-institutional outbreaks as an example, we show how within-sample diversity is partially maintained among repeated serial samples from the same host, it can transmitted between those cases with known epidemiological links, and how this improves phylogenetic inference and our understanding of who infected whom. Our technique is applicable to other infectious diseases and has immediate clinical utility in infection prevention and control.
-
- Genetics and Genomics
- Neuroscience
The Maillard reaction, a chemical reaction between amino acids and sugars, is exploited to produce flavorful food ubiquitously, from the baking industry to our everyday lives. However, the Maillard reaction also occurs in all cells, from prokaryotes to eukaryotes, forming Advanced Glycation End-products (AGEs). AGEs are a heterogeneous group of compounds resulting from the irreversible reaction between biomolecules and α-dicarbonyls (α-DCs), including methylglyoxal (MGO), an unavoidable byproduct of anaerobic glycolysis and lipid peroxidation. We previously demonstrated that Caenorhabditis elegans mutants lacking the glod-4 glyoxalase enzyme displayed enhanced accumulation of α-DCs, reduced lifespan, increased neuronal damage, and touch hypersensitivity. Here, we demonstrate that glod-4 mutation increased food intake and identify that MGO-derived hydroimidazolone, MG-H1, is a mediator of the observed increase in food intake. RNAseq analysis in glod-4 knockdown worms identified upregulation of several neurotransmitters and feeding genes. Suppressor screening of the overfeeding phenotype identified the tdc-1-tyramine-tyra-2/ser-2 signaling as an essential pathway mediating AGEs (MG-H1) induced feeding in glod-4 mutants. We also identified the elt-3 GATA transcription factor as an essential upstream regulator for increased feeding upon accumulation of AGEs by partially controlling the expression of tdc-1 gene. Further, the lack of either tdc-1 or tyra-2/ser-2 receptors suppresses the reduced lifespan and rescues neuronal damage observed in glod-4 mutants. Thus, in C. elegans, we identified an elt-3 regulated tyramine-dependent pathway mediating the toxic effects of MG-H1 AGE. Understanding this signaling pathway may help understand hedonistic overfeeding behavior observed due to modern AGEs-rich diets.